{"docstore/data": {"15b1e7c0-a55a-4ee8-a86a-b667818374bb": {"__data__": {"id_": "15b1e7c0-a55a-4ee8-a86a-b667818374bb", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54cda69d-0b0f-45ee-923d-47d2adac06c5", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. "}, "hash": "50078f6f9f6bc0c00d4eaaa212b2671b6607efeb84fdebee8903affdf51134ce", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. ", "start_char_idx": 0, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54cda69d-0b0f-45ee-923d-47d2adac06c5": {"__data__": {"id_": "54cda69d-0b0f-45ee-923d-47d2adac06c5", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15b1e7c0-a55a-4ee8-a86a-b667818374bb", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdcdfe33a68e4c7dc9ed85e20f2936e213e042bbee8d27e11846a3ee2c884624", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ebd334f-e3ad-4f56-93ed-d98766d8642f", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter. "}, "hash": "420c8d3e6a9449fdcdee3705951a6f8480415893d5303283603dd4b6794bb14a", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 544, "end_char_idx": 565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ebd334f-e3ad-4f56-93ed-d98766d8642f": {"__data__": {"id_": "4ebd334f-e3ad-4f56-93ed-d98766d8642f", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54cda69d-0b0f-45ee-923d-47d2adac06c5", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23b2107e1546683e1c220e88529b1d3712b449a62056b72020d358b2b4a2a8b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44bfbd15-d9fd-49fe-930b-71feffa4192f", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n"}, "hash": "8d71de2456a4d2b0357c43c5ea192204d26cbd4c62b3e3d3ec156e3ace14d665", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter. ", "start_char_idx": 565, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44bfbd15-d9fd-49fe-930b-71feffa4192f": {"__data__": {"id_": "44bfbd15-d9fd-49fe-930b-71feffa4192f", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ebd334f-e3ad-4f56-93ed-d98766d8642f", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a99ae9ed45fcca00df9cd217fae03b30368a20d14c30f21c50f6db8de2f8235", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. "}, "hash": "14c9e5bd346ab615f7b72e3b497e740b4965f09a664cfa148811afbc9f592eb4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "start_char_idx": 745, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82": {"__data__": {"id_": "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44bfbd15-d9fd-49fe-930b-71feffa4192f", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3f98256809f8b900bdc7d028102790e42fec4fdffc1fe40442dc83b7eb89de1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. "}, "hash": "ed85ed37fba46646ea238965ad87bc322c6b813e042a923e6c1b8cfbe45d451b", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "start_char_idx": 945, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b": {"__data__": {"id_": "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2023. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7820a68ee8bc54e2cf169145281ce36f3d9c4b0338014d733b79659186fed2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n"}, "hash": "4c3e0991b8a33ef2515059ac24a246e54144ad20fc6f504edd255111197aab71", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "start_char_idx": 1009, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8": {"__data__": {"id_": "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7fb47f8011a113fd8dbf51d7de39490c1ed23f4784ccfe44a12da9d65bb9052", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n"}, "hash": "93a4f01803a21509ce4811ef03955ea5958ebfe7da5fc441d23c1ba5ba18e7fe", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "start_char_idx": 1133, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd": {"__data__": {"id_": "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7991863b650730eb42d9c4a36c01bb8ca14eb19567d1f6e37ef66f125f15049d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896cd2e8-5806-40fd-8f0a-ea2628e6a024", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. "}, "hash": "0740ae7c807b17ade7aa74844becc94511c16e2049e619fb98825d053deb4d66", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1255, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896cd2e8-5806-40fd-8f0a-ea2628e6a024": {"__data__": {"id_": "896cd2e8-5806-40fd-8f0a-ea2628e6a024", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2023.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2b6e1941e01e3abd4006b98e7d55d3edffe777b231e5d13fba9bdb8c9be1031", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "Collis continued. "}, "hash": "d66981a2120ada7c9f2b4fa1f8856befb9438454406169b56a31ac937a009dd7", "class_name": "RelatedNodeInfo"}}, "text": "\u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "start_char_idx": 1564, "end_char_idx": 1781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825": {"__data__": {"id_": "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896cd2e8-5806-40fd-8f0a-ea2628e6a024", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2023 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "479dd8e88c671e1d12d93b587283a3466edf1342b6e191b42c17f7b17a9c5d38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6557afe0-45c2-40f3-b090-ebe21613a7f0", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1"}, "hash": "c1953106f0c2b815adce2105bcaeaa2e6cdc95e8b33cea257f080a88b491dea9", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1781, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6557afe0-45c2-40f3-b090-ebe21613a7f0": {"__data__": {"id_": "6557afe0-45c2-40f3-b090-ebe21613a7f0", "embedding": null, "metadata": {"window": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d96fd8386ff054548a1375e61eca6ced2f9a9eaddddb10b190317b83f55a1b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $11.30 to $11.60 to a range of $11.50 to $11.75.\n \u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fafd6261fe518b58f7733ef259673d2b0f44239ddfbba30a2cc7c695ceb424b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7987cd0-7555-4873-9819-61f60c9df33c", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "original_text": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "b315d2ced6cab5c49c5d765a93344a2facca166b8e0d2d1d2c20683b480003ee", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "start_char_idx": 1799, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7987cd0-7555-4873-9819-61f60c9df33c": {"__data__": {"id_": "c7987cd0-7555-4873-9819-61f60c9df33c", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "original_text": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6557afe0-45c2-40f3-b090-ebe21613a7f0", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered another quarter of solid results, and we are pleased to raise our full year outlook as a testament to\nour value creating approach to capital deployment and the resilience of our business,\u201d said Steven H. Collis, Chairman, President &\nChief Executive Officer of AmerisourceBergen.\n \u201cOur strong foundation in pharmaceutical distribution and complementary services create a compelling value proposition for our\npartners and customers at the center of global pharmaceutical innovation and access,\u201d Mr.  Collis continued.  \u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "original_text": "\u201cAs we look ahead, we\nare excited for our team members to be unified under our new corporate identity as Cencora later this year and to deliver on our\npurpose to create healthier futures.\u201d\nFirst Quar ter Fiscal Y ear 2023 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $62.8B $62.8B\nGross Pr ofit $2.1B $2.1B\nOperating Expenses $1.5B $1.4B\nOperating Income $633M $734M\nInterest Expense, Net $46M $46M\nEffectiv e Tax Rat e 19.8% 19.1%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $480M $560M\n1", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23058ad90fa3bef0e87204878fa23a104ce6a73ee6347fc45b4c1b68f66716a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c99447e-71b3-45a1-9554-0d2484aa9151", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "31c5eb52ffdb41464f193cb6a48b60995cb64a548ecac7458f13cf854659e14a", "class_name": "RelatedNodeInfo"}}, "text": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c99447e-71b3-45a1-9554-0d2484aa9151": {"__data__": {"id_": "2c99447e-71b3-45a1-9554-0d2484aa9151", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7987cd0-7555-4873-9819-61f60c9df33c", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "original_text": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3016fe7d4f4cef6cb10a568b004931b1dd3b2b5a836acc4ea0381f78816cd907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31de26dc-cb4a-4883-b3a2-e16b20fdfb68", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n"}, "hash": "23726be1b7953d2a03733c33b16d82fc23dcef58855bd4aaa9a484ea40fb3b43", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 206, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31de26dc-cb4a-4883-b3a2-e16b20fdfb68": {"__data__": {"id_": "31de26dc-cb4a-4883-b3a2-e16b20fdfb68", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c99447e-71b3-45a1-9554-0d2484aa9151", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66c168e343049991ec87fcf004b3261d6fe76c480726aa7f512160dfe527a7c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3157dac-10c8-4fae-aee2-d48e1e5f305a", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. "}, "hash": "15bf36367f14a86ef984ea209057f2b3392089d5a1273eb6bf0245967459a921", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "start_char_idx": 298, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3157dac-10c8-4fae-aee2-d48e1e5f305a": {"__data__": {"id_": "e3157dac-10c8-4fae-aee2-d48e1e5f305a", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31de26dc-cb4a-4883-b3a2-e16b20fdfb68", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1cf38a97d7d63ba4ab49306215c3fae868bef0810b19a4e0d5c8f3472351662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "767585d5-7f82-4157-b1b2-708bb2abe359", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n"}, "hash": "f7e3f3bc02b3a178225d1beb79d6bce2c8970eb5cf90763ed5cdf259a9f98d38", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "start_char_idx": 520, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "767585d5-7f82-4157-b1b2-708bb2abe359": {"__data__": {"id_": "767585d5-7f82-4157-b1b2-708bb2abe359", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3157dac-10c8-4fae-aee2-d48e1e5f305a", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "original_text": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bd43759e24e4af4db69bb851f5b8520753a8ec7f6f3af792c3357c9a739ecd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a451e02-04ec-4953-b340-52c537c67c07", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. "}, "hash": "e42a472295135d8cd93106a229c5fb5f1d6677170409418b9606461dbfb5fd71", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "start_char_idx": 753, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a451e02-04ec-4953-b340-52c537c67c07": {"__data__": {"id_": "2a451e02-04ec-4953-b340-52c537c67c07", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "767585d5-7f82-4157-b1b2-708bb2abe359", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8991bd2d0e3caa795b7c2d7d56c2dd56d68983f63ee08689c43b1379eae7cbe4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde71149-4758-4ef5-a17e-473523a42c48", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "original_text": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. "}, "hash": "c5ee297867428b2407225077c2b22bd2d5eaa13953ad46bee75158a8b4fa9d55", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "start_char_idx": 1109, "end_char_idx": 1323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde71149-4758-4ef5-a17e-473523a42c48": {"__data__": {"id_": "fde71149-4758-4ef5-a17e-473523a42c48", "embedding": null, "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "original_text": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a451e02-04ec-4953-b340-52c537c67c07", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "original_text": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17657e427acb2c95f0d76110c79835c99364c32122da529b83ea3a110132ae45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11", "node_type": "1", "metadata": {"window": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "original_text": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. "}, "hash": "293cce553de95deaa7ebfc412012f9e71dd043f33be1cf05d560fd71eb3d2c5a", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "start_char_idx": 1323, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11": {"__data__": {"id_": "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11", "embedding": null, "metadata": {"window": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "original_text": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde71149-4758-4ef5-a17e-473523a42c48", "node_type": "1", "metadata": {"window": "First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "original_text": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cd48437bb3a797a52777863dac95c75bea07fc0da251bd7014b2e5aa1d6209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "197ac244-55f8-4e3a-a0d0-b8d9653882b0", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n"}, "hash": "9bd205050f645921a6884ac4988e3d4c5d1117b3ef34d26dc302f979d4936b44", "class_name": "RelatedNodeInfo"}}, "text": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "start_char_idx": 1408, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "197ac244-55f8-4e3a-a0d0-b8d9653882b0": {"__data__": {"id_": "197ac244-55f8-4e3a-a0d0-b8d9653882b0", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11", "node_type": "1", "metadata": {"window": "Healthcare Solutions, offset in part by a 0.6 percent\ndecline in International Healthcare Solutions revenue primarily resulting from unfavorable foreign currency exchange rates in\nthe current year quarter in comparison to the prior year quarter, offset in part by an increase in sales in our less-than-wholly-\nowned Brazil full-line distribution business.\n Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "original_text": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4511e8ff6657786fd325e8fb34727a8abeb7ec8534296fb6183458eb2d957bc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e411bd-c1b8-42af-8cdf-fcd12868f0fd", "node_type": "1", "metadata": {"window": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. "}, "hash": "795253aa370d26ba4dbf6e7828e06cccd184a93c86bbfdb220bf733ac41192a3", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "start_char_idx": 1560, "end_char_idx": 1675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e411bd-c1b8-42af-8cdf-fcd12868f0fd": {"__data__": {"id_": "08e411bd-c1b8-42af-8cdf-fcd12868f0fd", "embedding": null, "metadata": {"window": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "197ac244-55f8-4e3a-a0d0-b8d9653882b0", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 4.2 percent increase compared to the same\nperiod in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "original_text": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b20e50b39a829fd72723a72b9e2d29ed6217c5ce527b8f91b11c63b8b2759f0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15bfd802-87f2-467e-8b79-664897e53bbe", "node_type": "1", "metadata": {"window": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. "}, "hash": "0f7d8efade2257ecdc288f5b694cd984823f69945165e6f80bcf9aa12347ab97", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "start_char_idx": 1675, "end_char_idx": 2006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15bfd802-87f2-467e-8b79-664897e53bbe": {"__data__": {"id_": "15bfd802-87f2-467e-8b79-664897e53bbe", "embedding": null, "metadata": {"window": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e411bd-c1b8-42af-8cdf-fcd12868f0fd", "node_type": "1", "metadata": {"window": "Healthcare Solutions and an increase in\ngains from antitrust litigation settlements.  The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "original_text": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81bb671add9625518267ba734a7de632168223b7dcb22e1e9497b02e6b80526d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32d63ee3-d045-493a-967d-7eaef97aac9b", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "original_text": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n"}, "hash": "71e517dd7d94583e669a0e79439a167faf09db0b0becdfb3263a6dbbae32b05c", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "start_char_idx": 2006, "end_char_idx": 2099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32d63ee3-d045-493a-967d-7eaef97aac9b": {"__data__": {"id_": "32d63ee3-d045-493a-967d-7eaef97aac9b", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "original_text": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15bfd802-87f2-467e-8b79-664897e53bbe", "node_type": "1", "metadata": {"window": "The increase in gross profit was partially offset by a LIFO expense in the current\nyear period versus a LIFO credit in the previous fiscal year period.  Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "original_text": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77c6b1a0192d8f1449f913d42daf3730ad49503083929c22bf83520c8328336b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "403b7d97-859c-4e07-8ed0-473859727237", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "original_text": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. "}, "hash": "eec9fe7052191c7a1ecfe13b76b041f628de693284d538bd69128c537be212b8", "class_name": "RelatedNodeInfo"}}, "text": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "start_char_idx": 2099, "end_char_idx": 2245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "403b7d97-859c-4e07-8ed0-473859727237": {"__data__": {"id_": "403b7d97-859c-4e07-8ed0-473859727237", "embedding": null, "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "original_text": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32d63ee3-d045-493a-967d-7eaef97aac9b", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.41 percent, a\ndecline of 5 basis points from the prior year quarter.\n Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "original_text": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df0c177eac75eca59c3cb98002ac7859d7e7fcf4f54f930cf9850f2e9608f2c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfbcedca-4a9d-4d76-b976-b7c2c89d412d", "node_type": "1", "metadata": {"window": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "original_text": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n"}, "hash": "0d25ab016146d5190ca2f93c1a0c8f63bf05e86630196d4523428c6cc887d675", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "start_char_idx": 2245, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfbcedca-4a9d-4d76-b976-b7c2c89d412d": {"__data__": {"id_": "cfbcedca-4a9d-4d76-b976-b7c2c89d412d", "embedding": null, "metadata": {"window": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "original_text": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "403b7d97-859c-4e07-8ed0-473859727237", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the first quarter of fiscal 2023, operating expenses were $1.5 billion, a 6.8 percent increase compared\nto the same period in the previous fiscal year, driven by an increase in distribution, selling, and administrative expenses\ncompared to the prior year quarter primarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "original_text": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9636497c2f9b3a2a13ddee531bb9eadc1a2a02c13dcb744bbb9a0925158db541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b4ca3ab-f6d5-4bff-9728-836b33105f44", "node_type": "1", "metadata": {"window": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n"}, "hash": "081e287ef56fc8bcf868fcdd8c37539e7b6b3825c63fec74f04b09e90f01674d", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "start_char_idx": 2686, "end_char_idx": 2853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b4ca3ab-f6d5-4bff-9728-836b33105f44": {"__data__": {"id_": "5b4ca3ab-f6d5-4bff-9728-836b33105f44", "embedding": null, "metadata": {"window": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfbcedca-4a9d-4d76-b976-b7c2c89d412d", "node_type": "1", "metadata": {"window": "Healthcare Solutions and inflationary impacts\non certain operating expenses in each segment.  The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "original_text": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff099fc58391f31fcd49c141071c03a9b51649f6ecd8acc1c86dad63d11708ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1057aad3-cf94-4132-96f7-2b7f3a71dfcf", "node_type": "1", "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. "}, "hash": "8fd233c24313a86c282a2f3529939c8e5c533aa1e5ed3144ca8b1755dfec268d", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "start_char_idx": 2853, "end_char_idx": 3145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1057aad3-cf94-4132-96f7-2b7f3a71dfcf": {"__data__": {"id_": "1057aad3-cf94-4132-96f7-2b7f3a71dfcf", "embedding": null, "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b4ca3ab-f6d5-4bff-9728-836b33105f44", "node_type": "1", "metadata": {"window": "The increase in distribution, selling, and administrative expenses was partially\noffset by a reduction of litigation and opioid-related expenses.\n Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a74d65801e4d7365963d005c41bd61642481537ad5caedd757edb7c2281a1060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34fbe4fb-7166-4810-9b53-a414d785e719", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "original_text": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n"}, "hash": "37338a696b1921aff50bc955440e8c245f4494d325a26f496aa962b1230c94f0", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "start_char_idx": 3145, "end_char_idx": 3244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34fbe4fb-7166-4810-9b53-a414d785e719": {"__data__": {"id_": "34fbe4fb-7166-4810-9b53-a414d785e719", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "original_text": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1057aad3-cf94-4132-96f7-2b7f3a71dfcf", "node_type": "1", "metadata": {"window": "Operating Income:  In the first quarter of fiscal 2023, operating income was $633.1 million, a 1.7 percent decrease compared\nto the same period in the previous fiscal year due to the decrease in operating income in International Healthcare Solutions\nresulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior year quarter\nand the June 2022 divestiture of our Brazil specialty business.  Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd3d75352046480420116507b5332c769e30430bd2f9128aa2c4ab839eaed561", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939fcbbe-9790-411a-9a9d-c563becca4a4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. "}, "hash": "da689a98f5f69ab844a62b37b6d74f52dd630148f8c6e60305ec61a85320153c", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "start_char_idx": 3244, "end_char_idx": 3412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939fcbbe-9790-411a-9a9d-c563becca4a4": {"__data__": {"id_": "939fcbbe-9790-411a-9a9d-c563becca4a4", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34fbe4fb-7166-4810-9b53-a414d785e719", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.01 percent\nin the first quarter of fiscal 2023, a decline of 7 basis points when compared to the prior year quarter.\n Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "original_text": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc0a91161cf4c903fb9f349859f7b8482f8475d36d79c68df950d5ea28258224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11514d0e-faa1-4480-972b-8cf0cbee0627", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "original_text": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n"}, "hash": "e4775608e24cd2e6e20ae8a17334949bf2b5841f9d0c45bbefb2a20c1f80cdf7", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "start_char_idx": 3412, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11514d0e-faa1-4480-972b-8cf0cbee0627": {"__data__": {"id_": "11514d0e-faa1-4480-972b-8cf0cbee0627", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "original_text": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939fcbbe-9790-411a-9a9d-c563becca4a4", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the first quarter of fiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the\nprior year quarter primarily due to an increase in interest income as a result of higher investment interest rates and higher\naverage investment cash balances.\n Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac579aec3389fcaac2a5d8ef55b4a31e02f5c6b225634bb828e6fadfb48a9981", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "665794a7-3fe6-4c9d-a59d-6b18b85488e7", "node_type": "1", "metadata": {"window": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n"}, "hash": "b0f85ff60c0199c7eb99ce0aa0498bfd193dff23ba64e2b805c63b1207a58def", "class_name": "RelatedNodeInfo"}}, "text": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "start_char_idx": 3601, "end_char_idx": 3702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "665794a7-3fe6-4c9d-a59d-6b18b85488e7": {"__data__": {"id_": "665794a7-3fe6-4c9d-a59d-6b18b85488e7", "embedding": null, "metadata": {"window": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11514d0e-faa1-4480-972b-8cf0cbee0627", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 19.8 percent for the first quarter of fiscal 2023.  This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "original_text": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78efc5ffdd1d3cf1d4a7b56783b117d50845b105a1c754c21422c8f22a0c164b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "f4f6c1e75f436975cd45dedc4901db445048135ccdafe0390e900456372b5ba4", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "start_char_idx": 3702, "end_char_idx": 3968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c": {"__data__": {"id_": "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "665794a7-3fe6-4c9d-a59d-6b18b85488e7", "node_type": "1", "metadata": {"window": "This compares to 24.6 percent in\nthe prior year quarter, which was negatively impacted by discrete tax expense associated with foreign valuation allowance\nadjustments.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f90be23fdd9ebb8e94efb130f457f41269f65b2af08d93c32cb787010b243bde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a416c874-637a-48ba-9b92-9986d737a006", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. "}, "hash": "242c7c02c15640df3b415d838497ce6b54f0c4c1cb4598419f5ff1da88ee19fb", "class_name": "RelatedNodeInfo"}}, "text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3968, "end_char_idx": 4085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a416c874-637a-48ba-9b92-9986d737a006": {"__data__": {"id_": "a416c874-637a-48ba-9b92-9986d737a006", "embedding": null, "metadata": {"window": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.33 in the first quarter of fiscal 2023, a 9.4 percent increase\ncompared to $2.13 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91b17daa7c79ef8168f7c6de00698ad4fa28614d4764f2b722942db956d85ad8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd1355bd-210f-4697-8a22-c1c6a91d5080", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2"}, "hash": "793f95e561365be76a9304bfd8d752b7a6dcc1a8e387e0e807ed00f53a1e1127", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "start_char_idx": 4085, "end_char_idx": 4279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd1355bd-210f-4697-8a22-c1c6a91d5080": {"__data__": {"id_": "dd1355bd-210f-4697-8a22-c1c6a91d5080", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5620b6f5a51d53280fabfdcc5a867213146a36e33c18d55c3107fe523818f1e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a416c874-637a-48ba-9b92-9986d737a006", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower effective tax rate and\na decrease in shares outstanding.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc112efb6801b1e92dd6a5a1d3668c4a4bffd89432ff9dd611d666257966d062", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe5490f3-fe33-448a-bbbe-58972cff51a0", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales. ", "original_text": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business. "}, "hash": "37f979b2fc3496ddf4f5e2f262245cb3d9c0e613782b4eaf0f479c9d2c7ae6c7", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "start_char_idx": 4279, "end_char_idx": 4388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe5490f3-fe33-448a-bbbe-58972cff51a0": {"__data__": {"id_": "fe5490f3-fe33-448a-bbbe-58972cff51a0", "embedding": null, "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales. ", "original_text": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd1355bd-210f-4697-8a22-c1c6a91d5080", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the first quarter of fiscal 2023 were 206.3\nmillion, a decrease of 4.8 million shares, or 2.3 percent versus the prior fiscal year first quarter primarily as a result of share\nrepurchases.\n First Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the first quarter of fiscal 2023, revenue was\n$62.8 billion, up 5.4 percent compared to the same quarter in the previous fiscal year, reflecting a 6.1 percent increase in\nrevenue within U.S.  Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "original_text": "Healthcare Solutions, offset in part by a 0.6 percent decline in International Healthcare Solutions revenue\n2", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0fcdc515814018c7ea5ea770d6d380a5dd9ca415226d183f6701fb1aac97002", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d7fd800-40a4-4dff-8b8a-cb15debe0045", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n"}, "hash": "3983ba4acf003e086dc47b7ac230f5de94bac11f5a715ee854cc7410ffe5157e", "class_name": "RelatedNodeInfo"}}, "text": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business. ", "start_char_idx": 0, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d7fd800-40a4-4dff-8b8a-cb15debe0045": {"__data__": {"id_": "4d7fd800-40a4-4dff-8b8a-cb15debe0045", "embedding": null, "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe5490f3-fe33-448a-bbbe-58972cff51a0", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales. ", "original_text": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d2e497d64696b0b336f3e9f5e8443ab6198f2ad99e43763caaf0f909bd605cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a079b3-002e-4f90-aca4-bf5cfe721d08", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S. "}, "hash": "c9464c0688eef5251a6674bc9ff108231b44ef3539f7390b0835e4428e755ca3", "class_name": "RelatedNodeInfo"}}, "text": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "start_char_idx": 247, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a079b3-002e-4f90-aca4-bf5cfe721d08": {"__data__": {"id_": "56a079b3-002e-4f90-aca4-bf5cfe721d08", "embedding": null, "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d7fd800-40a4-4dff-8b8a-cb15debe0045", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "original_text": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9dbc66b150604bdb1c33d4b21516056eef50a2f4837dda413dcb74849f3bf1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fce4c8c4-e877-495e-98a8-535098a314b5", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "original_text": "Healthcare Solutions, driven\nby increased sales. "}, "hash": "99902af24c4743152cc4b9149f48b86984fe9bd622110ca620074118ea278241", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "start_char_idx": 401, "end_char_idx": 633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fce4c8c4-e877-495e-98a8-535098a314b5": {"__data__": {"id_": "fce4c8c4-e877-495e-98a8-535098a314b5", "embedding": null, "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "original_text": "Healthcare Solutions, driven\nby increased sales. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a079b3-002e-4f90-aca4-bf5cfe721d08", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21f77bfa276a884d1a6a9c21b69eb89593dc96f19e711bdfd0c00d64a494948a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70b5da4a-8e39-4bd3-a8fc-984101b0b5de", "node_type": "1", "metadata": {"window": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n"}, "hash": "2583b67f4f138bac7e692222b7635c2ef4ded1c0dd6fd131d18bcf8b3352f58f", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions, driven\nby increased sales. ", "start_char_idx": 633, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70b5da4a-8e39-4bd3-a8fc-984101b0b5de": {"__data__": {"id_": "70b5da4a-8e39-4bd3-a8fc-984101b0b5de", "embedding": null, "metadata": {"window": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fce4c8c4-e877-495e-98a8-535098a314b5", "node_type": "1", "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "original_text": "Healthcare Solutions, driven\nby increased sales. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f667ea8e04e50049ea8a4368dbbee8d626c5e29cbea12b0c8ed9d7285a69b19d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe396e1-7f48-43be-83c2-9358273888d0", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. "}, "hash": "9b47effb20d92da92f655af748a00e604c82293afc5c04ba33874fd0006790de", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "start_char_idx": 682, "end_char_idx": 828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe396e1-7f48-43be-83c2-9358273888d0": {"__data__": {"id_": "afe396e1-7f48-43be-83c2-9358273888d0", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70b5da4a-8e39-4bd3-a8fc-984101b0b5de", "node_type": "1", "metadata": {"window": "On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "149d42e422a451b7c62cce7bdfbdcf94cec0c4d8a9ff27cf75094806f156fffb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a991c8ad-d945-46b0-b02d-b0d84e37e676", "node_type": "1", "metadata": {"window": "Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income. ", "original_text": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n"}, "hash": "bb802f8e5373f4fb9a864439e87023b21f76aa59c38c4d7dc48fa673831c5d5c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "start_char_idx": 828, "end_char_idx": 1121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a991c8ad-d945-46b0-b02d-b0d84e37e676": {"__data__": {"id_": "a991c8ad-d945-46b0-b02d-b0d84e37e676", "embedding": null, "metadata": {"window": "Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income. ", "original_text": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe396e1-7f48-43be-83c2-9358273888d0", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "original_text": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "601f8d056dc04030af85d42282cc7a17517b1456c1039fdd775571cef66452fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c274179a-5980-4e78-931c-637a694a0991", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. "}, "hash": "104ed957bfaa91c3f59cbfcdb05de650a46df436231f334710d924b7287e9659", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "start_char_idx": 1121, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c274179a-5980-4e78-931c-637a694a0991": {"__data__": {"id_": "c274179a-5980-4e78-931c-637a694a0991", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a991c8ad-d945-46b0-b02d-b0d84e37e676", "node_type": "1", "metadata": {"window": "Healthcare Solutions, driven\nby increased sales.  Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income. ", "original_text": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ab099f40f2bb14364d7d5d0d78884d5b06b006cb2bc118f55ca1e3df70efc0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. "}, "hash": "3e84527eb54ff76703a44a74214dbe65eb9f73266ec945c6109237a204b06459", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "start_char_idx": 1214, "end_char_idx": 1400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3": {"__data__": {"id_": "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c274179a-5980-4e78-931c-637a694a0991", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.38 percent in the fiscal 2023 first quarter, flat when\ncompared to the prior year quarter.\n Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "original_text": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e262f4a3694377f0d1b87430bd9a5877ec56a96bffb2cf534f9f629a06f1253", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ecec636-a153-4055-a531-c434d1d9babf", "node_type": "1", "metadata": {"window": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Healthcare Solutions operating income. "}, "hash": "9b1ada48aadcb1290dab303e25ab599b9da15e18dbb46314dc377ce13e54da90", "class_name": "RelatedNodeInfo"}}, "text": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "start_char_idx": 1400, "end_char_idx": 1750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ecec636-a153-4055-a531-c434d1d9babf": {"__data__": {"id_": "5ecec636-a153-4055-a531-c434d1d9babf", "embedding": null, "metadata": {"window": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Healthcare Solutions operating income. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the first quarter of fiscal 2023, adjusted operating expenses were $1.4 billion, a 9.8 percent\nincrease, driven by an increase in distribution, selling, and administrative expenses compared to the prior year quarter\nprimarily to support revenue growth in U.S.  Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "original_text": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "358de3b954308c41c021f85065c0014bcb9c8caed0a41e928122c4baaeec6f0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5060665-b5e1-4ccc-a22d-0ab74b811c83", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. "}, "hash": "90822077482bfd322ff1af994f1a3f6e902286a881ecb83b39840b9730306483", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions operating income. ", "start_char_idx": 1750, "end_char_idx": 1789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5060665-b5e1-4ccc-a22d-0ab74b811c83": {"__data__": {"id_": "b5060665-b5e1-4ccc-a22d-0ab74b811c83", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ecec636-a153-4055-a531-c434d1d9babf", "node_type": "1", "metadata": {"window": "Healthcare Solutions and inflationary impacts on certain operating expenses in\neach segment.\n Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Healthcare Solutions operating income. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab201ff951aa00c00f1e3b569c9fe264a004ea066283f6d0862c8c17e746dc20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2737015e-5317-48ac-85d1-7d625236503c", "node_type": "1", "metadata": {"window": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n"}, "hash": "0c7329eb6539ca819c4ab69f24ac02415acd963dfa75074dd8747ce844642ea5", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "start_char_idx": 1789, "end_char_idx": 1903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2737015e-5317-48ac-85d1-7d625236503c": {"__data__": {"id_": "2737015e-5317-48ac-85d1-7d625236503c", "embedding": null, "metadata": {"window": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5060665-b5e1-4ccc-a22d-0ab74b811c83", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the first quarter of fiscal 2023, adjusted operating income was $734 million, a 2.1 percent\ndecrease compared to the same period in the prior fiscal year.  The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "original_text": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9adcec549818057ec8f2a4d69c12831cfeaa386d2065d564f0c4d53a4ec0a25f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e75a9f66-3540-4a3e-b1dc-f4447912c6d9", "node_type": "1", "metadata": {"window": "Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "8a1f163ddf7376b2dc5dad64a4a8d5814db0df1682d5026b581d348d3004a24e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "start_char_idx": 1903, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e75a9f66-3540-4a3e-b1dc-f4447912c6d9": {"__data__": {"id_": "e75a9f66-3540-4a3e-b1dc-f4447912c6d9", "embedding": null, "metadata": {"window": "Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2737015e-5317-48ac-85d1-7d625236503c", "node_type": "1", "metadata": {"window": "The decrease was due to a 10.4 percent decrease in operating\nincome within International Healthcare Solutions resulting from unfavorable foreign currency exchange rates in the current\nyear quarter in comparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business, offset in\npart by a 0.6 percent increase in U.S.  Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4509928b25146030e4c5cf004de8b4df411d9ea7289338e1a7dcc08457869b73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e21864-44de-45cf-8a58-ee90d747b90a", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "original_text": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n"}, "hash": "db16d5d682e738e50d61dfaf66181dceebf7cc3d99bea9cf757aea1d2866d56e", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 2077, "end_char_idx": 2176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e21864-44de-45cf-8a58-ee90d747b90a": {"__data__": {"id_": "13e21864-44de-45cf-8a58-ee90d747b90a", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "original_text": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e75a9f66-3540-4a3e-b1dc-f4447912c6d9", "node_type": "1", "metadata": {"window": "Healthcare Solutions operating income.  On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c59ef741d2b039b3f599ff1f7ad07f5fa34eec7e39214e9798189c3fab1cef8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c8443f2-d873-4e0f-9c93-a78e8d953a84", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n"}, "hash": "f5412289f7cdc887a4ba350c6d622f34659214532d1bfe274191de00378034ff", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "start_char_idx": 2176, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c8443f2-d873-4e0f-9c93-a78e8d953a84": {"__data__": {"id_": "8c8443f2-d873-4e0f-9c93-a78e8d953a84", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e21864-44de-45cf-8a58-ee90d747b90a", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted operating\nincome increased 4.3 percent compared to the prior year quarter.  Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "original_text": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dc3e7b2c9bb2d88a1582f252ecfa0a4e3c29dada6d0a51788bb5c59efc8c597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dbe802e-d65f-4f23-a031-6e155663469c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. "}, "hash": "7be1a59db5e9e90dd039f954780b08a0dbd801054072b6d9cfa0695203b12ffd", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "start_char_idx": 2444, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dbe802e-d65f-4f23-a031-6e155663469c": {"__data__": {"id_": "9dbe802e-d65f-4f23-a031-6e155663469c", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c8443f2-d873-4e0f-9c93-a78e8d953a84", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.17 percent in the fiscal 2023 first quarter, a decrease of 9 basis points when compared to the prior year quarter.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e996b320efbfaf1abb3ce64b93e66cf53b3335c92d1a69f7ed4af598e3609d59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "757a4747-4c4c-4185-9d13-88424a46b17d", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. "}, "hash": "e01c70f01a2a9bc49fa2723ac33544d7d5672242a66a8a4c9784876b71430d90", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "start_char_idx": 2612, "end_char_idx": 2819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "757a4747-4c4c-4185-9d13-88424a46b17d": {"__data__": {"id_": "757a4747-4c4c-4185-9d13-88424a46b17d", "embedding": null, "metadata": {"window": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dbe802e-d65f-4f23-a031-6e155663469c", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8af1f9fa9f85215de68aff56ed35be8719fc35ea864c65c551a3f5b74fce0325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8478656-1f44-4cd0-9e72-89bf3bfc505d", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n"}, "hash": "761a88fbd2012967fca05827aab8f20e48f5269061688e9b65960f7d9cac3709", "class_name": "RelatedNodeInfo"}}, "text": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "start_char_idx": 2819, "end_char_idx": 2920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8478656-1f44-4cd0-9e72-89bf3bfc505d": {"__data__": {"id_": "c8478656-1f44-4cd0-9e72-89bf3bfc505d", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "757a4747-4c4c-4185-9d13-88424a46b17d", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2023, net interest expense of $46.0 million was down 13.8 percent versus the prior year quarter primarily due to an\nincrease in interest income as a result of higher investment interest rates and higher average investment cash balances.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "original_text": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "089a9f21401b3576f8e18006f8b27494a8bff8cb395cd968c19c369657d6188b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a724bed0-253a-471b-84fa-4116e09c3c21", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "8bfe076defc38327bfe249d0eb7cfb6b3c7736ae23c5ed8aaa2b04c54f4eeda9", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "start_char_idx": 2920, "end_char_idx": 3045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a724bed0-253a-471b-84fa-4116e09c3c21": {"__data__": {"id_": "a724bed0-253a-471b-84fa-4116e09c3c21", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8478656-1f44-4cd0-9e72-89bf3bfc505d", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 19.1 percent for the first quarter of fiscal 2023 compared to\n21.3 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "original_text": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f6aca4ed30ec8e8cc06c4b5b3c457b0544889265ae98b0761ea01378e22bf8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0de87473-b6b1-4fff-947f-b22f5a626084", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n"}, "hash": "c1ed93e9a96b2f2e00f7a2d774ee34f1b385fed4df79b27e0b724a5473b16859", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 3045, "end_char_idx": 3155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0de87473-b6b1-4fff-947f-b22f5a626084": {"__data__": {"id_": "0de87473-b6b1-4fff-947f-b22f5a626084", "embedding": null, "metadata": {"window": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a724bed0-253a-471b-84fa-4116e09c3c21", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $2.71 in the first quarter of fiscal 2023, a 5.0\npercent increase compared to $2.58 in the previous fiscal year\u2019s first quarter.  The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7db05af9cb641db3377057bcab9734a7dc53d7767b7bdb58b6ac88f021fbdfe8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a4cda22-09ea-4afc-8111-58c1f73c128b", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. "}, "hash": "bb7a6632574ae5b29e9c64d9bc3369736e4eec49e0f4239dd7e37a5197ee8acd", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "start_char_idx": 3155, "end_char_idx": 3392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a4cda22-09ea-4afc-8111-58c1f73c128b": {"__data__": {"id_": "8a4cda22-09ea-4afc-8111-58c1f73c128b", "embedding": null, "metadata": {"window": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0de87473-b6b1-4fff-947f-b22f5a626084", "node_type": "1", "metadata": {"window": "The increase was primarily due to the lower\neffective tax rate and a decrease in shares outstanding.  On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S. ", "original_text": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9a70fa78382f01a1a45dcab0908956261710397ab8f241ced3026e984117a9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff2bdccf-7052-419f-8f28-448d12f9b071", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n"}, "hash": "5a5621724867614c54d496de35e1f23afa3cd75d926585a14feb3425ced99e31", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "start_char_idx": 3392, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff2bdccf-7052-419f-8f28-448d12f9b071": {"__data__": {"id_": "ff2bdccf-7052-419f-8f28-448d12f9b071", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a4cda22-09ea-4afc-8111-58c1f73c128b", "node_type": "1", "metadata": {"window": "On a constant currency basis, adjusted diluted earnings per share\nincreased 10.5 percent compared to the prior year quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c4893f63154eb2b6f801267ccfefe9b6b01c0073db013956833951c0e739f62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb04fb34-3d5b-483b-b74a-cf239a7b1183", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "original_text": "U.S. "}, "hash": "db82a915218dcdccf1a36238f87cf871be240dcbc04c99bad49bb5e792e39a17", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and International Healthcare Solutions.\n", "start_char_idx": 3553, "end_char_idx": 3614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb04fb34-3d5b-483b-b74a-cf239a7b1183": {"__data__": {"id_": "bb04fb34-3d5b-483b-b74a-cf239a7b1183", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff2bdccf-7052-419f-8f28-448d12f9b071", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "Healthcare Solutions and International Healthcare Solutions.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8b1e55b5bf5ce64414869d7fdb0fa928ab5e02a8da8c0d767e5beefa5cbcc42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "605f6271-96d7-46fa-b2fd-62f66077e314", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "3dcba6be63eb75c35173294b284b5f33c1c43dcc24fac61785a8e64d8b82cd8e", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 628, "end_char_idx": 633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "605f6271-96d7-46fa-b2fd-62f66077e314": {"__data__": {"id_": "605f6271-96d7-46fa-b2fd-62f66077e314", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb04fb34-3d5b-483b-b74a-cf239a7b1183", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the first quarter of fiscal 2023 were 206.3 million, a decrease of 4.8 million shares, or\n2.3 percent versus the prior fiscal year first quarter primarily as a result of share repurchases.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6209355b2c41a9d064835432dca7dc6b471a08fe457832ef13038f0a304a7f4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95e6671c-7b31-4fb4-988c-2d2c0049d613", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. "}, "hash": "9b19df959d6e81996bec3164d01b545cd7604f28cd8757299120cfe5c2109495", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 3619, "end_char_idx": 3645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95e6671c-7b31-4fb4-988c-2d2c0049d613": {"__data__": {"id_": "95e6671c-7b31-4fb4-988c-2d2c0049d613", "embedding": null, "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "605f6271-96d7-46fa-b2fd-62f66077e314", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers under two reportable\nsegments: U.S.  Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fce2579bb6e735e92fa9e7dabca250657cafced6c24c4706d706624cf55513e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5763c603-49dc-4fa9-9c01-988b62fc461f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n"}, "hash": "c6b6018107c4e519828da6f6435caea1770ffd050b5a17ace7087c2825d96f92", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "start_char_idx": 3645, "end_char_idx": 3981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5763c603-49dc-4fa9-9c01-988b62fc461f": {"__data__": {"id_": "5763c603-49dc-4fa9-9c01-988b62fc461f", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95e6671c-7b31-4fb4-988c-2d2c0049d613", "node_type": "1", "metadata": {"window": "Healthcare Solutions and International Healthcare Solutions.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11b8d3f3ed3c1fb0f0d261b2a042aa596317f49fbdeac748c604cbcb3c056264", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3959970a-2948-4214-9ddb-880e8784849a", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3"}, "hash": "86e9346551e0f6dac38c2d4919020a762add6f6cd5276f02f9295e3973fe4b50", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "start_char_idx": 3981, "end_char_idx": 4307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3959970a-2948-4214-9ddb-880e8784849a": {"__data__": {"id_": "3959970a-2948-4214-9ddb-880e8784849a", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c8d1fe5c0d12bc5a2509f8ac39a8d9e160c3dfcf2eb86e8d2cbeedda1e7d24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5763c603-49dc-4fa9-9c01-988b62fc461f", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48c65f120e21be06f59a6d1df6c67793c9c6b83b3a1547cfced4075cd80b5019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25e0ea99-2c72-4f42-bb25-a759f249b9ae", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "original_text": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter. "}, "hash": "b4be3855f6f610f2b43046e370f7819736587c7d5e7bc471ffca12366356d97f", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\n3", "start_char_idx": 4307, "end_char_idx": 4343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25e0ea99-2c72-4f42-bb25-a759f249b9ae": {"__data__": {"id_": "25e0ea99-2c72-4f42-bb25-a759f249b9ae", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "original_text": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3959970a-2948-4214-9ddb-880e8784849a", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $56.2 billion in the first quarter of fiscal 2023, an increase of 6.1 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices, and\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $572.4 million in the first\nquarter of fiscal 2023 was up 0.6 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit and was largely offset by the increase in operating expenses, which included inflationary impacts on certain operating\nexpenses.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "373f884c5990ae1de4bc6650c38c017366b5a28529896443784a7829debe9f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2dcd19-e214-4fd8-be65-a86d238f33a1", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "original_text": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent. "}, "hash": "9d6f32d98eef63089529abeb55be6c70e5402dc88b1709adec3dfe161e64b3f0", "class_name": "RelatedNodeInfo"}}, "text": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter. ", "start_char_idx": 0, "end_char_idx": 173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e2dcd19-e214-4fd8-be65-a86d238f33a1": {"__data__": {"id_": "3e2dcd19-e214-4fd8-be65-a86d238f33a1", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "original_text": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e0ea99-2c72-4f42-bb25-a759f249b9ae", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "original_text": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30cc956f74bf29bde0f8dfe5f15c1473163f7b54062a253729c2794f2d7a13da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51f9f617-144b-4da9-96ad-55f82d55747d", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "original_text": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business. "}, "hash": "daad17e0fe0eb5673b3579e3fa7ba45df1837e9d20360308782621204c1aecf6", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent. ", "start_char_idx": 173, "end_char_idx": 282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51f9f617-144b-4da9-96ad-55f82d55747d": {"__data__": {"id_": "51f9f617-144b-4da9-96ad-55f82d55747d", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "original_text": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2dcd19-e214-4fd8-be65-a86d238f33a1", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "original_text": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c5aa13158c1abc7fe72e1dcbbfcb30a67784dec71f40e851ae4aa7818153e48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb9623f4-cf1b-41ab-8f5f-c4c952d98808", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n"}, "hash": "504ef0ae782640efc2940e23aa64352710b28c95a114c0252435bb33cf20d433", "class_name": "RelatedNodeInfo"}}, "text": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business. ", "start_char_idx": 282, "end_char_idx": 502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb9623f4-cf1b-41ab-8f5f-c4c952d98808": {"__data__": {"id_": "bb9623f4-cf1b-41ab-8f5f-c4c952d98808", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51f9f617-144b-4da9-96ad-55f82d55747d", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "original_text": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34e10cc4d271426b07e7dbe2b195a0a3535f8f7782bff50d493d967ab43e654b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eca8983b-f1bd-4232-8306-6ef8d05c1e02", "node_type": "1", "metadata": {"window": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "original_text": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. "}, "hash": "32cc10be158bfef805c1f0db63d55e87dc7994084a7af3dc9dbe309c5ae2fc31", "class_name": "RelatedNodeInfo"}}, "text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "start_char_idx": 502, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eca8983b-f1bd-4232-8306-6ef8d05c1e02": {"__data__": {"id_": "eca8983b-f1bd-4232-8306-6ef8d05c1e02", "embedding": null, "metadata": {"window": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "original_text": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb9623f4-cf1b-41ab-8f5f-c4c952d98808", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "original_text": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "652cc63ed673e5829d1d70adf6f3f4875d826f1182439cd26e5d810d29582d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "345eacb6-1636-40f1-9fcf-a96e24fa245f", "node_type": "1", "metadata": {"window": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "original_text": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. "}, "hash": "81a2c5c991b28a3ec02364ecce022fd5fcd029875933e74f0ae7872caa3a2b17", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "start_char_idx": 654, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "345eacb6-1636-40f1-9fcf-a96e24fa245f": {"__data__": {"id_": "345eacb6-1636-40f1-9fcf-a96e24fa245f", "embedding": null, "metadata": {"window": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "original_text": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eca8983b-f1bd-4232-8306-6ef8d05c1e02", "node_type": "1", "metadata": {"window": "Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "original_text": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6212d6c5a933c3dc43e09f67493278f874f377e99ad036c47bc007fc780683cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb2daec6-e492-4bbe-9973-da6f663cfe74", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "original_text": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n"}, "hash": "7f64785be53926e3755e26692f368926b99af7a449069779cd6c1c44f5267bdb", "class_name": "RelatedNodeInfo"}}, "text": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "start_char_idx": 766, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb2daec6-e492-4bbe-9973-da6f663cfe74": {"__data__": {"id_": "eb2daec6-e492-4bbe-9973-da6f663cfe74", "embedding": null, "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "original_text": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "345eacb6-1636-40f1-9fcf-a96e24fa245f", "node_type": "1", "metadata": {"window": "The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "original_text": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fd9b1e0501793fc1a96b15f8e34aef6bd21185c44ed77fa7eef4bc1e91a0bba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21028618-b0b3-4dd5-b9eb-c3e34ef45557", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "original_text": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. "}, "hash": "a83e9a765cbee9c24fdd2d1e7624069175d4582b888849f96232a276af0141c2", "class_name": "RelatedNodeInfo"}}, "text": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "start_char_idx": 943, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21028618-b0b3-4dd5-b9eb-c3e34ef45557": {"__data__": {"id_": "21028618-b0b3-4dd5-b9eb-c3e34ef45557", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "original_text": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb2daec6-e492-4bbe-9973-da6f663cfe74", "node_type": "1", "metadata": {"window": "On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "original_text": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7994ec0bdc9e96de913301945e85773821cc58478a2ab646cef403b4ef1282d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "291e11dc-f5a5-406a-a269-635a457c2305", "node_type": "1", "metadata": {"window": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "original_text": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. "}, "hash": "cf1fd660fa23bd18469b417e615411a0a12a2ded5b57985414ab734bbf3bf134", "class_name": "RelatedNodeInfo"}}, "text": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "start_char_idx": 1241, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "291e11dc-f5a5-406a-a269-635a457c2305": {"__data__": {"id_": "291e11dc-f5a5-406a-a269-635a457c2305", "embedding": null, "metadata": {"window": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "original_text": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21028618-b0b3-4dd5-b9eb-c3e34ef45557", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAnnounced the completion of the acquisition of PharmaLex Holding GmbH.  The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "original_text": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fae78e2b2fcb9cc155dab58061541fbdd0ab89d0424bfd2d2618fc26ed1cdbeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db832058-5154-4ccf-9031-5c822af6071d", "node_type": "1", "metadata": {"window": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n"}, "hash": "0897936070f51646d3c97d94f08b7b91257ffea99ab341b44ed33fa396d57316", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "start_char_idx": 1424, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db832058-5154-4ccf-9031-5c822af6071d": {"__data__": {"id_": "db832058-5154-4ccf-9031-5c822af6071d", "embedding": null, "metadata": {"window": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "291e11dc-f5a5-406a-a269-635a457c2305", "node_type": "1", "metadata": {"window": "The acquisition enhances AmerisourceBergen\u2019s\ngrowth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services\ncapabilities.  PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "original_text": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d39741928a6200ebc867c8a3871408c72bf411cf479288b41011dbe5b259dde3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20e90243-8f48-4f68-855e-4ba29f1f1baa", "node_type": "1", "metadata": {"window": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. "}, "hash": "cc46a776015de4ff428f03848bdf0dcf3510c881d78814294286e27db90180f8", "class_name": "RelatedNodeInfo"}}, "text": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "start_char_idx": 1522, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20e90243-8f48-4f68-855e-4ba29f1f1baa": {"__data__": {"id_": "20e90243-8f48-4f68-855e-4ba29f1f1baa", "embedding": null, "metadata": {"window": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db832058-5154-4ccf-9031-5c822af6071d", "node_type": "1", "metadata": {"window": "PharmaLex\u2019s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality\nmanagement and compliance services expand AmerisourceBergen\u2019s role as partner of choice for biopharmaceutical partners\nacross the pharmaceutical development and commercialization journey.\n On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a70e3c978ca3c4799c33498f451de3c0c287fff39244a00d0d85394fe735f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48eb52d4-fd32-47d3-8875-f9e8c471d698", "node_type": "1", "metadata": {"window": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "original_text": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n"}, "hash": "b6df1a2bd5d66b0b42f3306e204e31c29e5672b0e36f16413503547e81043fe9", "class_name": "RelatedNodeInfo"}}, "text": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "start_char_idx": 1813, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48eb52d4-fd32-47d3-8875-f9e8c471d698": {"__data__": {"id_": "48eb52d4-fd32-47d3-8875-f9e8c471d698", "embedding": null, "metadata": {"window": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "original_text": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20e90243-8f48-4f68-855e-4ba29f1f1baa", "node_type": "1", "metadata": {"window": "On January 24, 2023, AmerisourceBergen announced it intends to change its name to Cencora to better reflect its bold vision\nand purpose-driven approach to creating healthier futures.  AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6b200f79c19f010eb9c6a551009229d12db333c19566384d0dbb40550690161", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21172005-daa3-4378-826c-8ec471f82e70", "node_type": "1", "metadata": {"window": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "07c3b834071e9ae27da5a18c11ba6f87032c843573dd3f1400d577be0967777a", "class_name": "RelatedNodeInfo"}}, "text": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "start_char_idx": 1994, "end_char_idx": 2127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21172005-daa3-4378-826c-8ec471f82e70": {"__data__": {"id_": "21172005-daa3-4378-826c-8ec471f82e70", "embedding": null, "metadata": {"window": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48eb52d4-fd32-47d3-8875-f9e8c471d698", "node_type": "1", "metadata": {"window": "AmerisourceBergen intends to begin operating as Cencora in the\nsecond half of calendar year 2023.  Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "original_text": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d479d625974f72abb555e93b7d5cd6e352be7a0c6d8d1f817a9a4598d224db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ab02006-a659-453d-853a-0cb0e964161e", "node_type": "1", "metadata": {"window": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "6d932ffcc5775ed3d14907989b16fcd83be42859ac74bb8790da493ffa382547", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 2127, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ab02006-a659-453d-853a-0cb0e964161e": {"__data__": {"id_": "7ab02006-a659-453d-853a-0cb0e964161e", "embedding": null, "metadata": {"window": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21172005-daa3-4378-826c-8ec471f82e70", "node_type": "1", "metadata": {"window": "Operating as Cencora, a unified and internationally inclusive name and brand, the\nCompany will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform\nof pharma and biopharma services to support pharmaceutical innovation and access.\n On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "original_text": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82096129b874ce31794029337fe12c3f3884ee8d17a54ca6dbe6ddd85544fb0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bb765d5-2968-499a-b58a-891d7655b3e6", "node_type": "1", "metadata": {"window": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. "}, "hash": "bcf83fa51ec37d8b46990a3c63471e344bba8ee266ae44ea0d89d15ea87973a6", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 2371, "end_char_idx": 2503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bb765d5-2968-499a-b58a-891d7655b3e6": {"__data__": {"id_": "4bb765d5-2968-499a-b58a-891d7655b3e6", "embedding": null, "metadata": {"window": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ab02006-a659-453d-853a-0cb0e964161e", "node_type": "1", "metadata": {"window": "On January 27, 2023, AmerisourceBergen released its 2022 ESG Reporting Index and microsite, detailing the impact of its\nenvironmental, social, and governance programs and progress.  For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5ed231c0ad1734f5fa9cd2dea499bb5412653625998d729bc705c19f83c970b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "original_text": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated. "}, "hash": "d55eccd608bd021a669271b45133ec9aac16b0637ee6932f0fb597a230ad5dd5", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "start_char_idx": 2503, "end_char_idx": 2893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215": {"__data__": {"id_": "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "original_text": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bb765d5-2968-499a-b58a-891d7655b3e6", "node_type": "1", "metadata": {"window": "For the fifth year in a row, selected information within the\n2022 report was assured by ERM Certification and Verification Services.\n Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "original_text": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56267df12065b7c689aae680ccb018a00ec14c31d41c25d37e10c576a38ee979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d5e55b6-56ad-452e-864c-b90064c7845d", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n"}, "hash": "0b9b11606f478366faa8996a831f5ff902a4e4c7e900695dc15cd9060c06bf8a", "class_name": "RelatedNodeInfo"}}, "text": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "start_char_idx": 2893, "end_char_idx": 2979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d5e55b6-56ad-452e-864c-b90064c7845d": {"__data__": {"id_": "0d5e55b6-56ad-452e-864c-b90064c7845d", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "original_text": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d49aca75e78aeb0842ce6efffb23b454e7f75f6f60626f8e1824d3097a346c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dea15763-144f-4bf3-a06c-214a7be8e21d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. "}, "hash": "98578f23ea9aa7fa000ed8fe3061b9ed1d23bd7acfe090c444e23a1de934b467", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "start_char_idx": 2979, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dea15763-144f-4bf3-a06c-214a7be8e21d": {"__data__": {"id_": "dea15763-144f-4bf3-a06c-214a7be8e21d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d5e55b6-56ad-452e-864c-b90064c7845d", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df3f6daf84d1e932f81cfef86161187317c8aa3879895c51b1a7d43e00d95e38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9102cdb-223c-4de5-b441-14db59edbb01", "node_type": "1", "metadata": {"window": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. "}, "hash": "d3d5ce2b88357cc66515d7c4d2ebe3021a14d9750a080b9f3ca53f86631a97a0", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "start_char_idx": 3717, "end_char_idx": 3944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9102cdb-223c-4de5-b441-14db59edbb01": {"__data__": {"id_": "f9102cdb-223c-4de5-b441-14db59edbb01", "embedding": null, "metadata": {"window": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dea15763-144f-4bf3-a06c-214a7be8e21d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2023 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2023 financial guidance to reflect a lower average diluted share count, the earlier-\nthan-expected close of the Company\u2019s acquisition of PharmaLex, updated foreign currency translation rates and incrementally lower\nexpectations for COVID treatment contributions for the year.  Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6aea733d43029e5d09ca726041f3b84e5af260dce071f37281dc7a1decd9427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b77fa293-2edf-42a7-b64a-b43e887075cb", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4"}, "hash": "e9b1ffc74f0e93f2448de746a5bd0d74423eb4dee4d047dc1358b1fa7ce909b6", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "start_char_idx": 3944, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b77fa293-2edf-42a7-b64a-b43e887075cb": {"__data__": {"id_": "b77fa293-2edf-42a7-b64a-b43e887075cb", "embedding": null, "metadata": {"window": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a9f502a5-4335-49bd-8223-0791e4b172c3", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d26a862e36f59f91f49eb4a4bf2ee828dbe5697bd37d02d0106e664179aa260", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9102cdb-223c-4de5-b441-14db59edbb01", "node_type": "1", "metadata": {"window": "Growth rates are on an as reported basis unless constant currency\nbasis is indicated.  The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1e1e571620327ba11095f1c4674305b89dbffba41383e5f4a7522d4f3db615e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "699349b9-f0fc-4d12-82d0-c332caefcc25", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n"}, "hash": "33aeaabead3a5812e5ce09175f23d6cb03c05a55614154c8117259f647636b98", "class_name": "RelatedNodeInfo"}}, "text": "Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "start_char_idx": 4102, "end_char_idx": 4382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "699349b9-f0fc-4d12-82d0-c332caefcc25": {"__data__": {"id_": "699349b9-f0fc-4d12-82d0-c332caefcc25", "embedding": null, "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b77fa293-2edf-42a7-b64a-b43e887075cb", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted Earnings Per Share to be in the range of $11.50 to $11.75, representing growth of 4 to 7 percent, raised from\nthe previous range of $11.30 to $11.60;\nOn a constant currency basis, adjusted diluted earnings per share growth to be in the range of 6 to 9 percent, raised\nfrom the previous range of 4 to 7 percent;\nExcluding contributions related to COVID-19, adjusted diluted earnings per share growth to be in the range of 9 to 11\npercent, raised from the previous range of 7 to 9 percent;\nOn a constant currency basis excluding contributions related to COVID-19, adjusted diluted earnings per share\ngrowth to be in the range of 11 to 13 percent, raised from the previous range of 9 to 11 percent.\n Additional expectations now include:\nExcluding contributions related to COVID-19, adjusted consolidated operating income growth in the range of 4 percent to 6\npercent, up from the previous range of 3 percent to 5 percent;\nU.S.  Healthcare Solutions segment operating income growth to be in the range of 1 percent to 4 percent, widened from the\nprevious range of 2 percent to 4 percent.  Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "original_text": "Expectations for segment operating income growth excluding COVID-19\ncontributions remain unchanged;\nInternational Healthcare Solutions segment operating income to be in the range of a 3 percent decline to 1 percent growth,\nup from the previous range of a 7 to 3 percent decline;\n4", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c724b745e84cf7f2c22fd85d8da9a82c843afecce73acbb87ad9bd343f6bb3c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdd0e06c-714e-45b2-b834-acf54caaccae", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n"}, "hash": "8eac59d9248a5fedcf02f2c3adedc6d813fbe30e47d6c20be27662615369cf27", "class_name": "RelatedNodeInfo"}}, "text": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n", "start_char_idx": 0, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdd0e06c-714e-45b2-b834-acf54caaccae": {"__data__": {"id_": "fdd0e06c-714e-45b2-b834-acf54caaccae", "embedding": null, "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "699349b9-f0fc-4d12-82d0-c332caefcc25", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62aa5627ee7715c0fa1ee40d332455732f00d2fae45fe70235307c6488e6c1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0421e8a4-2589-4bad-8fb5-68f7501bb891", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n"}, "hash": "2f48447dbec2e3ec90b3ed2791f68b70bc1b7483d9697264cbbcbc8624e2b83b", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n", "start_char_idx": 354, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0421e8a4-2589-4bad-8fb5-68f7501bb891": {"__data__": {"id_": "0421e8a4-2589-4bad-8fb5-68f7501bb891", "embedding": null, "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdd0e06c-714e-45b2-b834-acf54caaccae", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023. ", "original_text": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3341a552ceafb8b79391677e829f82ef17c2e7bee459faf3cbafe58c3e825074", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "494bbb25-2e97-4aa8-8c60-a6712e37df85", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "1f5e78fbff0233eac62214b2261e7dca6f83f33057931a0846243a6073cb7624", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n", "start_char_idx": 482, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "494bbb25-2e97-4aa8-8c60-a6712e37df85": {"__data__": {"id_": "494bbb25-2e97-4aa8-8c60-a6712e37df85", "embedding": null, "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0421e8a4-2589-4bad-8fb5-68f7501bb891", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "original_text": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b54ed62cbd3da2bec5d03ab316f02e81c688711a043aec9ab8a75e208dcaca5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e048306-925b-4ae9-8ce2-2827e4cc4c81", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on February 1, 2023. "}, "hash": "6ae3894174e1621b0aa2861c5ade5d708646f9a75629150bbdbe74742fbf1cdc", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 699, "end_char_idx": 814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e048306-925b-4ae9-8ce2-2827e4cc4c81": {"__data__": {"id_": "5e048306-925b-4ae9-8ce2-2827e4cc4c81", "embedding": null, "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on February 1, 2023. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "494bbb25-2e97-4aa8-8c60-a6712e37df85", "node_type": "1", "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "836035f0f6b2794beface1853a65706e17f987796e71238827ceb3fef1e669ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a5f89d1-9384-4246-84fd-14944aaa72fe", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. "}, "hash": "79d7a96ee616b57e2b815360b551f5a7341a7a85d9c0f562e9a61b874dad4d47", "class_name": "RelatedNodeInfo"}}, "text": "ET on February 1, 2023. ", "start_char_idx": 814, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a5f89d1-9384-4246-84fd-14944aaa72fe": {"__data__": {"id_": "5a5f89d1-9384-4246-84fd-14944aaa72fe", "embedding": null, "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e048306-925b-4ae9-8ce2-2827e4cc4c81", "node_type": "1", "metadata": {"window": "All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on February 1, 2023. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c6ad1d8559b9928657b3e370621d011a54c404dba95b4f4b31ae7cf8298bdc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d910207-a785-4cab-a84e-4ace90d34875", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. "}, "hash": "e9a5843aadab8da4b9eec04cdff7da876357f4792230e37e77bb895fed3d8a2f", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "start_char_idx": 838, "end_char_idx": 954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d910207-a785-4cab-a84e-4ace90d34875": {"__data__": {"id_": "4d910207-a785-4cab-a84e-4ace90d34875", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a5f89d1-9384-4246-84fd-14944aaa72fe", "node_type": "1", "metadata": {"window": "Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e32650f813542db3cddc5d9885268c96c3067f767fabee164eca7a55ff43711f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5", "node_type": "1", "metadata": {"window": "ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. "}, "hash": "c2f794ed7c620256b006af37c7416c5d04f22d8aa536a09c30cd45c11b8ad7d0", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "start_char_idx": 954, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5": {"__data__": {"id_": "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5", "embedding": null, "metadata": {"window": "ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d910207-a785-4cab-a84e-4ace90d34875", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b99281368efadf872fd805c010ee5f6f44d71f7371cecba97e588aac6f36696f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccdca928-32b5-4d84-a630-c4e2d3989e9c", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 310213. "}, "hash": "571c79f4baaf3adabe7891d1c7c0bbf191a70905d11409e1e306748779a0c41e", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "start_char_idx": 1193, "end_char_idx": 1260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccdca928-32b5-4d84-a630-c4e2d3989e9c": {"__data__": {"id_": "ccdca928-32b5-4d84-a630-c4e2d3989e9c", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 310213. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5", "node_type": "1", "metadata": {"window": "ET on February 1, 2023.  A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06ff58167dab2f038fb517b1c9a303de28ddefbd84394dd82f6694b577e8be2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4f77887-d0e0-43a9-bc4d-60b42a7acaae", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. "}, "hash": "2c71136184ebd509319740d751c7c53f20daf09aa137359e78e0a4c37860d497", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 310213. ", "start_char_idx": 1260, "end_char_idx": 1305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4f77887-d0e0-43a9-bc4d-60b42a7acaae": {"__data__": {"id_": "b4f77887-d0e0-43a9-bc4d-60b42a7acaae", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccdca928-32b5-4d84-a630-c4e2d3989e9c", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company\u2019s website at investor.amerisourcebergen.com.  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 310213. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e79e91f1e7b6a524b2939399c6e16f465ebaf2c3692f685d1b9d7004d9ab5f18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f146e8cc-7eb2-4315-a6ca-f905310b9f2c", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "774d3ed229b75ca4e8fad1d611fc9dd148ac517fc5c8651d8c8080aecb2bdd72", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "start_char_idx": 1305, "end_char_idx": 1401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f146e8cc-7eb2-4315-a6ca-f905310b9f2c": {"__data__": {"id_": "f146e8cc-7eb2-4315-a6ca-f905310b9f2c", "embedding": null, "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4f77887-d0e0-43a9-bc4d-60b42a7acaae", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e62d2c2216f1c925a9fb88bd4e59b523169822db79cf7fbe14a7fc2f978b7ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "e03da9190778ea2c4a70397c17fd09266dfc8bce16d70f532606e175267f8a87", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 1401, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a": {"__data__": {"id_": "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f146e8cc-7eb2-4315-a6ca-f905310b9f2c", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2464494ead24bfb8d17696e8a98f1090b272f3fdb2fb4a6675637371d38367b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f159e87-6b94-4026-8502-8926a87a351f", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "665794127c353235633041e4a3f30ac45e41a283d2800ddeb38913fc47fd8407", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1524, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f159e87-6b94-4026-8502-8926a87a351f": {"__data__": {"id_": "6f159e87-6b94-4026-8502-8926a87a351f", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 310213.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9efa90ce97b1346581c2ae02c650dce1e5487edadb6a07f6dcd965eb5065d9ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6a94759-6f4f-4d24-b44a-9ff3da919f16", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "f5efe44ee59ce347c36a8ae16d09be386f3b1cf41ace247186490b1846a45192", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 1594, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6a94759-6f4f-4d24-b44a-9ff3da919f16": {"__data__": {"id_": "e6a94759-6f4f-4d24-b44a-9ff3da919f16", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f159e87-6b94-4026-8502-8926a87a351f", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com.  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b019a8761f0778d7972bf604fe56d47c5fcd87ce81b3794a7a19d2cbfe65fffe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbfaca59-780a-4316-982a-db79b85b31f7", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n", "original_text": "To access the telephone replay from within the U.S. "}, "hash": "3645802d5d3bfa1b5bc319d05414efef78a0c6b8728d1914e0cb3c8f6cb0dbe6", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1763, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbfaca59-780a-4316-982a-db79b85b31f7": {"__data__": {"id_": "bbfaca59-780a-4316-982a-db79b85b31f7", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6a94759-6f4f-4d24-b44a-9ff3da919f16", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34acd4a5e8c4b6bb81028822193bcb1796cea7c1dbf74fa1f8a536bd007003d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7926e76b-afda-4f16-8805-b5a72d4cf770", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "e979c260eea924677e2ded8ddcde0397bccce1b4ce2222fbd7031c489e26ff19", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S. ", "start_char_idx": 1905, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7926e76b-afda-4f16-8805-b5a72d4cf770": {"__data__": {"id_": "7926e76b-afda-4f16-8805-b5a72d4cf770", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbfaca59-780a-4316-982a-db79b85b31f7", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "296b8c4d0c31ce622af3f2aad72977464207536102029b5390e41eee747505f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e78a047-26a7-45a1-8adb-c671cca3a18a", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. "}, "hash": "adf3e5a0e5a81d24c23c4a15050f53401fede3804762822873fecccb05213afc", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 1957, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e78a047-26a7-45a1-8adb-c671cca3a18a": {"__data__": {"id_": "2e78a047-26a7-45a1-8adb-c671cca3a18a", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7926e76b-afda-4f16-8805-b5a72d4cf770", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4989e117b3330d5fb6b2f3d07ed313a3a395d03d3224cd5215be4ee534bf79c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6283bb1d-fda4-4239-b923-553a3225d5a5", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "original_text": "The access code for the replay is 802410.\n"}, "hash": "b2fdf077af99c76a4e6d1206f75ecc4f2bfa33539cc94729e58c196b1884aacd", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "start_char_idx": 1990, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6283bb1d-fda4-4239-b923-553a3225d5a5": {"__data__": {"id_": "6283bb1d-fda4-4239-b923-553a3225d5a5", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "original_text": "The access code for the replay is 802410.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e78a047-26a7-45a1-8adb-c671cca3a18a", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0de9cb2177518bba836f75ac7cca2c085f243d0c84e8faabaa48b4898dddd38b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b08f357-75d3-4702-8826-f8bc86c03386", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n"}, "hash": "a53ba25f5580358d177b2be7a6350c883e5cad154695d76dae67fa2febb8666d", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 802410.\n", "start_char_idx": 2058, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b08f357-75d3-4702-8826-f8bc86c03386": {"__data__": {"id_": "6b08f357-75d3-4702-8826-f8bc86c03386", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6283bb1d-fda4-4239-b923-553a3225d5a5", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "original_text": "The access code for the replay is 802410.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "236fe635eea441d0903a2bf39d2fa5d066169e2b79422796a831920a24978b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9469b69f-9994-428c-96bf-48afc44fbdf1", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. "}, "hash": "2efee0c0695b9b33bd857dd1b476c5e6493c77a50cecbde7e79ad090ad412350", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "start_char_idx": 2100, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9469b69f-9994-428c-96bf-48afc44fbdf1": {"__data__": {"id_": "9469b69f-9994-428c-96bf-48afc44fbdf1", "embedding": null, "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b08f357-75d3-4702-8826-f8bc86c03386", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2174042c77f792a6cdc25b74ff5ccd1bfb8a7e67922122a3440baf299322bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e77e9336-dd87-4997-a87c-a7669b9ad69c", "node_type": "1", "metadata": {"window": "The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. "}, "hash": "6f6525cbc2940502ca2accd60e4e89129483470dfa8eb967d6a7da3dcefc5fd4", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "start_char_idx": 2283, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e77e9336-dd87-4997-a87c-a7669b9ad69c": {"__data__": {"id_": "e77e9336-dd87-4997-a87c-a7669b9ad69c", "embedding": null, "metadata": {"window": "The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9469b69f-9994-428c-96bf-48afc44fbdf1", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54c2e7fa067deb09b2b399f91fa2388810736f7d6d1cae26b37af3bd6dd8620d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. "}, "hash": "d4e0f90fe37dfd3ef6b4b22d76370e600e7054ed41dea51276c3cf4482dee542", "class_name": "RelatedNodeInfo"}}, "text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "start_char_idx": 2457, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8": {"__data__": {"id_": "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e77e9336-dd87-4997-a87c-a7669b9ad69c", "node_type": "1", "metadata": {"window": "The access code for the replay is 802410.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "original_text": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fc5f0d5a1a63dae7821afdf64574a9b4630c50cb1e8e5732e1d732dc402d128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d3ffbc3-5ed4-4d35-8367-af13dfab9320", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "1ac7ac01e2338fc6e8ec62798cf1dfa4f79fa5bd0e5fb92c35ec265674236c97", "class_name": "RelatedNodeInfo"}}, "text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "start_char_idx": 2577, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d3ffbc3-5ed4-4d35-8367-af13dfab9320": {"__data__": {"id_": "2d3ffbc3-5ed4-4d35-8367-af13dfab9320", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBarclays Global Healthcare Conference March 14-16, 2023.\n About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n", "original_text": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90e024fd23e46f3c65db03db931f02a350956053c7a3677cf6d7c93ba6c13b9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0", "node_type": "1", "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. "}, "hash": "cf94ec9f0dda38f3c2cc2b227648b6e8de2cde003c94ba8632a091f42f58b13e", "class_name": "RelatedNodeInfo"}}, "text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 2695, "end_char_idx": 2868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0": {"__data__": {"id_": "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0", "embedding": null, "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d3ffbc3-5ed4-4d35-8367-af13dfab9320", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals\naround the world.  We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "original_text": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c5275a5e5320ac60b1b6180dd3e2b4d37d08b5d53a388120aed84f802799ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5af2fc8-b068-4e50-b1fc-53b902634dcf", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Learn more at investor.amerisourcebergen.com.\n"}, "hash": "8d6e4ecc4af5705bbbbbdb6bc1b7959b2412cc4a9bcdbf72c7dd4274230918b4", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "start_char_idx": 2868, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5af2fc8-b068-4e50-b1fc-53b902634dcf": {"__data__": {"id_": "e5af2fc8-b068-4e50-b1fc-53b902634dcf", "embedding": null, "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0", "node_type": "1", "metadata": {"window": "We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to\ntherapies.  Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue. ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4590b3f041a9e5b0ceaf0195cdfebe0626ac20e4f86415f1847b04f28cc4ea5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4fce91-76e0-4395-b5aa-a64c95c35a52", "node_type": "1", "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). "}, "hash": "211199d4d6d36c48db78e79bd62562b0795169f5ba1b8cb474c3cd8eb501efaf", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com.\n", "start_char_idx": 3000, "end_char_idx": 3046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4fce91-76e0-4395-b5aa-a64c95c35a52": {"__data__": {"id_": "bf4fce91-76e0-4395-b5aa-a64c95c35a52", "embedding": null, "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5af2fc8-b068-4e50-b1fc-53b902634dcf", "node_type": "1", "metadata": {"window": "Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.  Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Learn more at investor.amerisourcebergen.com.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd0414d7fb1742e02b18e98642851afecf31c65d15405c3775e6b1ef46f9fa6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5"}, "hash": "1af8d7b1f01ad3427e49c57caf723de46d622c8d84798ffc353c71696e3c608b", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "start_char_idx": 3046, "end_char_idx": 3393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5": {"__data__": {"id_": "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af3278b2-63d4-4163-ae9b-c159922c35aa", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92616493f5c283f69f21950791db6d198a07a43816f0ef0979de6a36616dd373", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4fce91-76e0-4395-b5aa-a64c95c35a52", "node_type": "1", "metadata": {"window": "Our\n44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d). ", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c8aa6f200be0ea311c74beecf8ee821be1c898de4c7822492d5b0f066c794bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eef8b813-89ed-4245-8570-cfc722b06c59", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "original_text": "similar expressions are intended to identify such forward-looking statements. "}, "hash": "0b264a545bb9a3a68e768c3d03eeaba450326c802154687ffa45faa2526687b6", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "start_char_idx": 3393, "end_char_idx": 3665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eef8b813-89ed-4245-8570-cfc722b06c59": {"__data__": {"id_": "eef8b813-89ed-4245-8570-cfc722b06c59", "embedding": null, "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "original_text": "similar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500\nwith more than $200 billion in annual revenue.  Learn more at investor.amerisourcebergen.com.\n Amerisour ceBer gen\u2019s Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \u201cforward-looking statements\u201d within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cSecurities Exchange\nAct\u201d).  Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "original_text": "Words such as \u201cexpect,\u201d \u201clikely,\u201d \u201coutlook,\u201d \u201cforecast,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccan,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201ccontinue,\u201d\n\u201csustain,\u201d \u201csynergy,\u201d \u201con track,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cpossible,\u201d \u201cassume,\u201d variations of such words, and\n5", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0c9804313a93d3756c4b88dd9f3382b48ea661bc5bbaa44cb1bc648a682371e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24829ef8-6bc6-4b34-8466-cdd0a2f17cad", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "aa90b1ba2068a81c08e961751074ab905768ca52ec175f153007925ae9a295e3", "class_name": "RelatedNodeInfo"}}, "text": "similar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 0, "end_char_idx": 78, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24829ef8-6bc6-4b34-8466-cdd0a2f17cad": {"__data__": {"id_": "24829ef8-6bc6-4b34-8466-cdd0a2f17cad", "embedding": null, "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eef8b813-89ed-4245-8570-cfc722b06c59", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "original_text": "similar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f059b6cc2ca835235243dca4893fc004b7797eb8dfdc0898599003afe19cb2c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74fbd71d-0b62-47b9-aa34-7d77d1dae430", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. "}, "hash": "a7d53fa188b82eb959bdd267d25c0bbf4c7b8905bd0d6e94ef40438a1d5ca68f", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 78, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74fbd71d-0b62-47b9-aa34-7d77d1dae430": {"__data__": {"id_": "74fbd71d-0b62-47b9-aa34-7d77d1dae430", "embedding": null, "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24829ef8-6bc6-4b34-8466-cdd0a2f17cad", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "original_text": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2adbe69d84c8a39538b5e64af4d6aea17584cc673a0e048aab9b6c03ebb746e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e3b232b-053a-446b-95ea-a5f9af1fffd2", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. "}, "hash": "adb3c947438346c68083a9fcf972df423480da91dd7429493398bf097f4ebd37", "class_name": "RelatedNodeInfo"}}, "text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "start_char_idx": 240, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e3b232b-053a-446b-95ea-a5f9af1fffd2": {"__data__": {"id_": "3e3b232b-053a-446b-95ea-a5f9af1fffd2", "embedding": null, "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74fbd71d-0b62-47b9-aa34-7d77d1dae430", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f730ea2c20219c03014a17b9b341150a1b3e56d59834cb96067bcd82f729260", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a622475-2df3-4c04-8bdf-508c272803fe", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. "}, "hash": "6321cf862a6fd19524cf31183400e3b9f53e425ea61c785d38c30db987f0f550", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 439, "end_char_idx": 4163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a622475-2df3-4c04-8bdf-508c272803fe": {"__data__": {"id_": "5a622475-2df3-4c04-8bdf-508c272803fe", "embedding": null, "metadata": {"window": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e3b232b-053a-446b-95ea-a5f9af1fffd2", "node_type": "1", "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2432511464aad8c411ea314f8d7b204a4eaa5db76494b89a303396b7a00a022", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6ec5399-f0b8-492c-bb14-cdad36aafcc7", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n"}, "hash": "07a1740fa4826436bcbfe9947bf01808ba4bfea42159cee6f02e1011009c3b0c", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "start_char_idx": 4163, "end_char_idx": 4373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6ec5399-f0b8-492c-bb14-cdad36aafcc7": {"__data__": {"id_": "e6ec5399-f0b8-492c-bb14-cdad36aafcc7", "embedding": null, "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a622475-2df3-4c04-8bdf-508c272803fe", "node_type": "1", "metadata": {"window": "These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cdfc3e060630f31c7e3a0a8959abf24e224c8de1983fab6a1a4dd63d43dc67e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19fba8d1-c28e-4332-991f-b426328b270a", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. "}, "hash": "a5d7a701a0cdab71403ccfce8a8d2aed2796fdf4a599692083b5d57b7f503a12", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "start_char_idx": 4373, "end_char_idx": 6317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19fba8d1-c28e-4332-991f-b426328b270a": {"__data__": {"id_": "19fba8d1-c28e-4332-991f-b426328b270a", "embedding": null, "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6ec5399-f0b8-492c-bb14-cdad36aafcc7", "node_type": "1", "metadata": {"window": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c95816ff7526aee970bd43d8953caa39b27391184773ad542db91c934b91f78c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0b92e8d-0d16-43b2-9677-6484973a13b8", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n"}, "hash": "415c2df5a52081dedcf1995fe1d62b9dc712b79f1dac57f809c586e4c9f874d0", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "start_char_idx": 6317, "end_char_idx": 6732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b92e8d-0d16-43b2-9677-6484973a13b8": {"__data__": {"id_": "a0b92e8d-0d16-43b2-9677-6484973a13b8", "embedding": null, "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19fba8d1-c28e-4332-991f-b426328b270a", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19e1f9fdd9fe36141be1267eb7ac0c89196c11947073e104da5d4d6a6b87480b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8649ee9-3320-4c00-86a4-c37a5ce3d779", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "6"}, "hash": "3c9f895d27ab68b83e365cc789952976ee0d078bdd199e5410f0fd7d949e5f82", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "start_char_idx": 6732, "end_char_idx": 6881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8649ee9-3320-4c00-86a4-c37a5ce3d779": {"__data__": {"id_": "d8649ee9-3320-4c00-86a4-c37a5ce3d779", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "6", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75cbe2302177fe891a4de4d73d571734c0dacf2fcd5a3e0947564e53e0c48b90", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0b92e8d-0d16-43b2-9677-6484973a13b8", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including noncompliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e7616be394dbbca53fc5e96bea3f9b2b586724212308d05f43e8b1cdfbcde2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "463ef6fd-52a1-4bc1-8563-5b0624d9c1d4", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7"}, "hash": "bf4bd21874f912c1ceb1be4206ba8688312f28d6adbb8970d3e2d7b92a691681", "class_name": "RelatedNodeInfo"}}, "text": "6", "start_char_idx": 6881, "end_char_idx": 6882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "463ef6fd-52a1-4bc1-8563-5b0624d9c1d4": {"__data__": {"id_": "463ef6fd-52a1-4bc1-8563-5b0624d9c1d4", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0849c01-d9f1-4fb3-b380-1baa6576b7a1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02844c02ffc47e5828b7c613acec1bcd0a91df6c687a09015c130b5a76febf4a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8649ee9-3320-4c00-86a4-c37a5ce3d779", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond\nto financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company\u2019s\ntax positions and/or the Company\u2019s tax liabilities or adverse resolution of challenges to the Company\u2019s tax positions; loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial market volatility and disruption; financial\nand other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction,\nfailure or breach of sophisticated information systems to operate as designed; risks generally associated with cybersecurity; risks\ngenerally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of\nmacroeconomic and geopolitical trends and events, including the unfolding situation in Russia and Ukraine and its regional and\nglobal ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s\noperations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign\noperations), resulting in a charge to earnings; the Company\u2019s ability to manage and complete divestitures; the disruption of the\nCompany\u2019s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign\ncurrency exchange rate fluctuations; declining economic conditions and increases in inflation in the United States and abroad; and\nother economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company\u2019s business generally.\n Certain additional factors that management believes could cause actual outcomes and results to differ materially from those\ndescribed in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for\nthe fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the\nSecurities Exchange Act.  The Company undertakes no obligation to publicly update or revise any forward-looking statements,\nexcept as required by the federal securities laws.\n 6", "original_text": "6", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80c9a2b427f0dd2f252160024f4885d8225230c375688d4e712d8cc27e5c767d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c2e36b3-6bbd-4f28-88da-b427633f0404", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n"}, "hash": "c8088216d9b9879e35f29efda46cc62fd79b79a9bc19064c2ca91c7c4e571600", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "start_char_idx": 0, "end_char_idx": 1199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c2e36b3-6bbd-4f28-88da-b427633f0404": {"__data__": {"id_": "5c2e36b3-6bbd-4f28-88da-b427633f0404", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa3d582ab02d7e545f7753e00422380c656a579d4194a33f1d58ea5e4347794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "463ef6fd-52a1-4bc1-8563-5b0624d9c1d4", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a80570ceab04cff1f198e024e5bfacaed5cb29afb140252090b69365ab6337bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n"}, "hash": "bb923f197e289aa9f5b20cefd45699cadb8bee9d80477035aaa870edcfd1d648", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n", "start_char_idx": 0, "end_char_idx": 831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444": {"__data__": {"id_": "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa3d582ab02d7e545f7753e00422380c656a579d4194a33f1d58ea5e4347794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c2e36b3-6bbd-4f28-88da-b427633f0404", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a884e6d94ca95f959900717ab14c5d53413e45362da7faf613b27541dd03cb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f26af49-1cd8-45ca-9efe-2f65c776e289", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8"}, "hash": "00ef42a41fc53f570d97625ea44a469e6036377f3f153f35bd5341b7ae6e5745", "class_name": "RelatedNodeInfo"}}, "text": "Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n", "start_char_idx": 831, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f26af49-1cd8-45ca-9efe-2f65c776e289": {"__data__": {"id_": "2f26af49-1cd8-45ca-9efe-2f65c776e289", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "faa3d582ab02d7e545f7753e00422380c656a579d4194a33f1d58ea5e4347794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba5625d029c2f059b188e0c8c58e58cce50df4124e111edd924446e734803b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620725a9-7f47-4be9-8b56-0e805e27fb60", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9"}, "hash": "31e7f8f909d4c29c0a05b4ca2222672552c857f365dffbc768827f1b21c80031", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "start_char_idx": 911, "end_char_idx": 1027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620725a9-7f47-4be9-8b56-0e805e27fb60": {"__data__": {"id_": "620725a9-7f47-4be9-8b56-0e805e27fb60", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "713e24e1-1374-496d-8092-46a267204fd0", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24979020415f2a8c50aeead180f2950e4e731b9475d647337bf39b29ebb0ab2c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f26af49-1cd8-45ca-9efe-2f65c776e289", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfd38b8a3ccfc84c7794b1c7e4cf73076d625af99219c3cc24fc4031598ba743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cff24e4-a003-46a3-9834-00a8695f9027", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. "}, "hash": "7781ee94e119fed8650da23c9711bf7472d9e0dc9c977ced6a83ebe27450119a", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "start_char_idx": 0, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cff24e4-a003-46a3-9834-00a8695f9027": {"__data__": {"id_": "1cff24e4-a003-46a3-9834-00a8695f9027", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3093538-a13a-442c-a1be-33f757d9c7c4", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1899602af8d7021b4cdbfeb6e1bf64c71e9b4106d8a7702ef42dd141404be7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620725a9-7f47-4be9-8b56-0e805e27fb60", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fee452964fe680aaef577a36dc79e4c9380eb69875368b6ef5d4bf6ce978294", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42293786-271e-4381-88a1-e4eab57a42e0", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n"}, "hash": "405857e18ffcf63f19dbced76833b41445252773837b5535d2c04ef5fd2e8f51", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "start_char_idx": 0, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42293786-271e-4381-88a1-e4eab57a42e0": {"__data__": {"id_": "42293786-271e-4381-88a1-e4eab57a42e0", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3093538-a13a-442c-a1be-33f757d9c7c4", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1899602af8d7021b4cdbfeb6e1bf64c71e9b4106d8a7702ef42dd141404be7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cff24e4-a003-46a3-9834-00a8695f9027", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34bb931b6fa77303cd12337f3395689eb9ac6acc67ed7b513af0eb856db0a239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c29b67fd-47f5-4755-bc01-ebf63b5d60cb", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "114cc6be5b1c1e882d1536647594f73e640bab8bddc2d1c3df9295533008990d", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "start_char_idx": 168, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c29b67fd-47f5-4755-bc01-ebf63b5d60cb": {"__data__": {"id_": "c29b67fd-47f5-4755-bc01-ebf63b5d60cb", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3093538-a13a-442c-a1be-33f757d9c7c4", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1899602af8d7021b4cdbfeb6e1bf64c71e9b4106d8a7702ef42dd141404be7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42293786-271e-4381-88a1-e4eab57a42e0", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d073df7536f7b6994e75bec49e152773e12d3f21d05455659a2cac8284c27f27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51f9dbe4-b365-4a81-8151-e2f0b5d145fc", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10"}, "hash": "19b6b66071f4e429c32c65f350c414a2bd1eeef14021d9d42564920c537da26e", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 611, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51f9dbe4-b365-4a81-8151-e2f0b5d145fc": {"__data__": {"id_": "51f9dbe4-b365-4a81-8151-e2f0b5d145fc", "embedding": null, "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3093538-a13a-442c-a1be-33f757d9c7c4", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1899602af8d7021b4cdbfeb6e1bf64c71e9b4106d8a7702ef42dd141404be7e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c29b67fd-47f5-4755-bc01-ebf63b5d60cb", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00c0b11ec3ec5e7343bebc2ed55019e588a4043d193c7bfea04dbcbf2a227f0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7a87305-1c03-4cbe-9d37-662e676df42b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11"}, "hash": "2f2319e6d1c85aab367d3382d000e8ff62a7e87ac29fd091af70878324a95ba7", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "start_char_idx": 788, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7a87305-1c03-4cbe-9d37-662e676df42b": {"__data__": {"id_": "c7a87305-1c03-4cbe-9d37-662e676df42b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "page_label": "11", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45cf4069-78c8-41e6-977a-0973d85f37d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0c82881a7c1d4f0fe739fc077fb5ec020aee5681cf32edc9aaad13c6d8b678d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51f9dbe4-b365-4a81-8151-e2f0b5d145fc", "node_type": "1", "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e80f16fec4f1fa11cc267cfba5bae64692637c027961254ffb4fdd75a10b853f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "991a4e59-e8ed-4f20-a613-131406a31e07", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n"}, "hash": "fc09985252d70504bdebc9dc029e4dcbb9560e7ed2c097abe10a676013fd83db", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "start_char_idx": 0, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "991a4e59-e8ed-4f20-a613-131406a31e07": {"__data__": {"id_": "991a4e59-e8ed-4f20-a613-131406a31e07", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8af6d44a900d97ce41702531aaa9a9180329e69648b1ca4dcb215ac756779d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7a87305-1c03-4cbe-9d37-662e676df42b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "page_label": "11", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5fd923e0b9c5ceb370d118e6c972a6670a664e20e6d7bee16190cdebfea7b1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d820226-35fb-41f2-bdd0-b4d328b0c4b9", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "6d120011d43e66286b72bfce7eba21f7fce0f47157032f51cbf0abb51cefb8eb", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d820226-35fb-41f2-bdd0-b4d328b0c4b9": {"__data__": {"id_": "5d820226-35fb-41f2-bdd0-b4d328b0c4b9", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8af6d44a900d97ce41702531aaa9a9180329e69648b1ca4dcb215ac756779d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "991a4e59-e8ed-4f20-a613-131406a31e07", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ac47517b31080876a459f21758543c9949ad44153b0869c3ab3e3fcb49748ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. "}, "hash": "b892d50b2114f67e1b5feec9684a901c7a2c37bd8565ccdb68ca8e35c62005d9", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 227, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877": {"__data__": {"id_": "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8af6d44a900d97ce41702531aaa9a9180329e69648b1ca4dcb215ac756779d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d820226-35fb-41f2-bdd0-b4d328b0c4b9", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43d675d0338fa9ccaaf942850a91e76556b22018cb86e8e446328b61f933ccc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09893472-d7d3-45e4-ae97-ea9ff99893ed", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. "}, "hash": "1fa73a71c0eef6f844000617418a0975cf5f43e3e7484adcc4a94cb07bc47716", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 404, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09893472-d7d3-45e4-ae97-ea9ff99893ed": {"__data__": {"id_": "09893472-d7d3-45e4-ae97-ea9ff99893ed", "embedding": null, "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8af6d44a900d97ce41702531aaa9a9180329e69648b1ca4dcb215ac756779d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2af7acc6b530efb6549d1445ac4ec69562127a34407ba9b90043e228b78b8eef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a61571f-c90e-46d3-a85a-03be966d723f", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12"}, "hash": "3cdca19acb686104c07b7d43575970318f4a853ee3437b18a0839ac476c7bd33", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "start_char_idx": 560, "end_char_idx": 847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a61571f-c90e-46d3-a85a-03be966d723f": {"__data__": {"id_": "2a61571f-c90e-46d3-a85a-03be966d723f", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8af6d44a900d97ce41702531aaa9a9180329e69648b1ca4dcb215ac756779d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09893472-d7d3-45e4-ae97-ea9ff99893ed", "node_type": "1", "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "198175c348e20130c8977e6ac9e01ddc653f6ec07d19489de3500295abf4efbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f484c5a0-9183-4de6-bd44-bf0c775f220b", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "2b9c65c4d030017239a3a38a221e794ef1e38d876f2d9a4da5a944c74a82fcd4", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "start_char_idx": 847, "end_char_idx": 1199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f484c5a0-9183-4de6-bd44-bf0c775f220b": {"__data__": {"id_": "f484c5a0-9183-4de6-bd44-bf0c775f220b", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8df1153-61d9-4086-a54c-90fb35aee650", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43ab3ac68f4531e47fd4f81506816abb35dffd19e5f7d03f5f6b139adc07578b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a61571f-c90e-46d3-a85a-03be966d723f", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S.  Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "original_text": "Healthcare Solutions \u00a0$572,416 \u00a0\u00a0$569,087 \u00a0\u00a00.6 %\nInternational Healthcare Solutions \u00a0\u00a0161,282 \u00a0\u00a0\u00a0180,060 \u00a0\u00a0(10.4 )%\nTotal segment operating income \u00a0\u00a0733,698 \u00a0\u00a0\u00a0749,147 \u00a0\u00a0(2.1 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a049,899 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nTurkey highly inflationary impact \u00a0\u00a0(3,584 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO (expense) credit \u00a0\u00a0(25,050 )\u00a0\u00a044,679 \u00a0\u00a0\u00a0\n12", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8f38dc82ced8ed944d6df140d4fc60d4aef498667316273871a3b8786557b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "233542f9-e350-4022-a3da-3bf9402dc884", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13"}, "hash": "5f94bb104a7cce1441f2540329532d9f65d21059138fc2c7aa77dc542f059eb1", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 0, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "233542f9-e350-4022-a3da-3bf9402dc884": {"__data__": {"id_": "233542f9-e350-4022-a3da-3bf9402dc884", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8df1153-61d9-4086-a54c-90fb35aee650", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43ab3ac68f4531e47fd4f81506816abb35dffd19e5f7d03f5f6b139adc07578b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f484c5a0-9183-4de6-bd44-bf0c775f220b", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70fbf29bda7f32177ad9d119288a8ec19f1066ef51dbc0685c19a424ba74986d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2efeb5ca-96a8-493a-9681-e03f5da1cc3e", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n"}, "hash": "64824cf04c2a9b369ba35633254d015849f2f913aca7de21c0414e130f10a75e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "start_char_idx": 359, "end_char_idx": 1017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2efeb5ca-96a8-493a-9681-e03f5da1cc3e": {"__data__": {"id_": "2efeb5ca-96a8-493a-9681-e03f5da1cc3e", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b1d2ece-37c9-4a21-9b9d-4923baf01d43", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3729b94c06d618c880592377b414f16ccd0f4b65befff7e60c10fff88d656a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "233542f9-e350-4022-a3da-3bf9402dc884", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "789178013fa3277af2ee77d32c88682a69724a19239b51ff3d7a6123a80ec17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8e963b5-a1fb-4612-b01a-fa55c58724d1", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14"}, "hash": "89a6b4755ac5f87cf9343b8b14e97840cb1cae9957a5eb57c5c9f9df9841c3c2", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "start_char_idx": 0, "end_char_idx": 177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8e963b5-a1fb-4612-b01a-fa55c58724d1": {"__data__": {"id_": "e8e963b5-a1fb-4612-b01a-fa55c58724d1", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b1d2ece-37c9-4a21-9b9d-4923baf01d43", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3729b94c06d618c880592377b414f16ccd0f4b65befff7e60c10fff88d656a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2efeb5ca-96a8-493a-9681-e03f5da1cc3e", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0396834813224834112400ad09fa2438406ed507d27fc77d8486edc2f439378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9a4bbae-c69c-47fb-b20e-90e09456745a", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n"}, "hash": "a4325ee42893fcdb82d7882f738ef72a6df4e7d16b8fe1b0750fa89f050364b0", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "start_char_idx": 177, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9a4bbae-c69c-47fb-b20e-90e09456745a": {"__data__": {"id_": "e9a4bbae-c69c-47fb-b20e-90e09456745a", "embedding": null, "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n", "page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "53d4e1d4-c77a-4a8b-b9aa-b5d54e88c264", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a944788dd8de08a51cc7cc4783dfa07d6004cf0c782a218ee2850fa614e58db4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8e963b5-a1fb-4612-b01a-fa55c58724d1", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c23367a490a12f49a7557d9f412e06c102750d8536b9b3d0c17e6793bf61ba8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "853bb4da-dd21-4d07-b717-30becb8139f1", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15"}, "hash": "c17c39312f57a9583d2c969145d57a1ff0d23849dc94dce63f82580dbf9a896b", "class_name": "RelatedNodeInfo"}}, "text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n", "start_char_idx": 0, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "853bb4da-dd21-4d07-b717-30becb8139f1": {"__data__": {"id_": "853bb4da-dd21-4d07-b717-30becb8139f1", "embedding": null, "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "53d4e1d4-c77a-4a8b-b9aa-b5d54e88c264", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a944788dd8de08a51cc7cc4783dfa07d6004cf0c782a218ee2850fa614e58db4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9a4bbae-c69c-47fb-b20e-90e09456745a", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n", "page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6116dbe347ac3597b47e80e49b2f8cde2572241b5207c07c7a0c6e25f5496e7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "897d6b41-1940-4a67-8cf8-d9cd8e35c771", "node_type": "1", "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16"}, "hash": "f5541508c7fc2ec52b1238cad06303cc3d606d75ad6dc96aa8987b18cdf8f362", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "start_char_idx": 682, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "897d6b41-1940-4a67-8cf8-d9cd8e35c771": {"__data__": {"id_": "897d6b41-1940-4a67-8cf8-d9cd8e35c771", "embedding": null, "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "32bbbc25-898e-463a-a9cc-6761b80b482f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b1fe054b3046c022defa7b892de4835ac18dcd1a4d65e88bda263d299fc1e7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "853bb4da-dd21-4d07-b717-30becb8139f1", "node_type": "1", "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c13dd612444f272c206b3023216f1852b358cb1ac7791c070f402b02a47b628b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c815a577-c922-4ea0-b458-b87fc28c2345", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n"}, "hash": "8df868005a8bd41010e8415861d8e99ea672127169a36484e3150610dc88d324", "class_name": "RelatedNodeInfo"}}, "text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "start_char_idx": 0, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c815a577-c922-4ea0-b458-b87fc28c2345": {"__data__": {"id_": "c815a577-c922-4ea0-b458-b87fc28c2345", "embedding": null, "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "897d6b41-1940-4a67-8cf8-d9cd8e35c771", "node_type": "1", "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "754ec21987c29d0391d50dc5bb989280e8d9145b4987f16ecc0d5ba49d921aa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a55b2fb3-6709-4de1-ad01-657f23414d97", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "f9d9be2261cbc53dc15bcedf28417336b0b49436080ba656dc132099c5333b47", "class_name": "RelatedNodeInfo"}}, "text": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a55b2fb3-6709-4de1-ad01-657f23414d97": {"__data__": {"id_": "a55b2fb3-6709-4de1-ad01-657f23414d97", "embedding": null, "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c815a577-c922-4ea0-b458-b87fc28c2345", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "512f14e9a8f6690132ed4f4871d059046c8ab30f787ffd30ed4028ea076e7cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cee8086-d8ae-4a14-be00-b01f7412cff3", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "aaa7a6e8049e209676c8042c8ca63a91e330db1d3683b3414aab48c3a59e9ac1", "class_name": "RelatedNodeInfo"}}, "text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 501, "end_char_idx": 1303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cee8086-d8ae-4a14-be00-b01f7412cff3": {"__data__": {"id_": "0cee8086-d8ae-4a14-be00-b01f7412cff3", "embedding": null, "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a55b2fb3-6709-4de1-ad01-657f23414d97", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "736e4ed27001b460518c413dccafc14fb8a41d351500930d1de16f37d0667d36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "60cd570be2538104b4158ab5afd4ba9af68144558ac554d1e464112c320e0121", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1303, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3": {"__data__": {"id_": "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3", "embedding": null, "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cee8086-d8ae-4a14-be00-b01f7412cff3", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "610d4d33adb93c39a9654afe5348bbd20b15f4963d5c61cfc2727e08e0e3545f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee17db7-d3b5-47b1-8bd0-d7137be7edf0", "node_type": "1", "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "eb0f54392d70bfa9e8415ea24066400015b91e7b3af976dd64c52eee2a0705c9", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1418, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee17db7-d3b5-47b1-8bd0-d7137be7edf0": {"__data__": {"id_": "bee17db7-d3b5-47b1-8bd0-d7137be7edf0", "embedding": null, "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3", "node_type": "1", "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23744521a7dc3d4ba1e5709cf7bd79cd10e5095e8c2b579c1d4041e740264e33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8c019b6-4e27-4a44-92dd-128a81c40aba", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "b884d7d5ef4c3bacad61eb35c3fddb7d7d5d4925d95e3f61648dcf570d4e3f27", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1558, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8c019b6-4e27-4a44-92dd-128a81c40aba": {"__data__": {"id_": "c8c019b6-4e27-4a44-92dd-128a81c40aba", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee17db7-d3b5-47b1-8bd0-d7137be7edf0", "node_type": "1", "metadata": {"window": "2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71f3173e77cb88bab54313eb4260810004345686945ba39523e93accd9d4b6ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f783ba94-d8cc-4998-8a33-24e0d2023452", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "e1e0a67eac6fc31e79af311e83bdefcaee0b234151bdcf6a6b6403280ccc3fe3", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1677, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f783ba94-d8cc-4998-8a33-24e0d2023452": {"__data__": {"id_": "f783ba94-d8cc-4998-8a33-24e0d2023452", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8c019b6-4e27-4a44-92dd-128a81c40aba", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c93c073906e4d5faebe1e597782405509a2fe0a5029828154472b2eee636c9ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7501f904-8e46-4ec6-88ab-0a11659a9612", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17"}, "hash": "447b5bfcab0637165c3693d4728bd97233d0e6919eed80cbb188c114c2843a24", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 1896, "end_char_idx": 2078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7501f904-8e46-4ec6-88ab-0a11659a9612": {"__data__": {"id_": "7501f904-8e46-4ec6-88ab-0a11659a9612", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "90356f82-f373-469d-b5cf-20856364a6b5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a845ea917542fe4fd0ceff2723bac9bfd272d39f8285e5a0b00576bb1fb3853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f783ba94-d8cc-4998-8a33-24e0d2023452", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4bd914dc73185de28c885f399c12b78d2e49e1999ea870a2cbbf0f9a6c53ae9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "6cca6702272c6b5bf827bc2b4d5037f8fe4c8d74ee94fd305cafda2748e82339", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "start_char_idx": 2078, "end_char_idx": 2283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33": {"__data__": {"id_": "0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33", "embedding": null, "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7501f904-8e46-4ec6-88ab-0a11659a9612", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\n17", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ef3ffcd1ac6c4d2fa41ff1a034e695a0a0ffeb5fa7d34324545bb94ba60931f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7b8351f-558c-454c-a751-5d1b3dd1d644", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). "}, "hash": "a9dd909b01a99566b45613e71a88e4bcbbb6301bcd10d1ce2124ba99ad1c8ecc", "class_name": "RelatedNodeInfo"}}, "text": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 0, "end_char_idx": 78, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7b8351f-558c-454c-a751-5d1b3dd1d644": {"__data__": {"id_": "a7b8351f-558c-454c-a751-5d1b3dd1d644", "embedding": null, "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5503c9fa8f4f8c9e78b3faba653de5f61ecc13bb9b9bd17133a61dd4c098952e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "741ae356-8ec9-424d-9ae8-43b6aef35994", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. "}, "hash": "1c859dc7c931b58deef377051cc12e2e3cb87d3d81246f94f51ee9106a9032ad", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "start_char_idx": 78, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "741ae356-8ec9-424d-9ae8-43b6aef35994": {"__data__": {"id_": "741ae356-8ec9-424d-9ae8-43b6aef35994", "embedding": null, "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7b8351f-558c-454c-a751-5d1b3dd1d644", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit). ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0416af2c9ab74b1df3ca6ab0607d967fb59d386eeac209ba7130023e06e200ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06ee30e1-d439-4efe-a16d-c86c9ac337f8", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "0d7effa0325ab5ccd8673bf71c7ed2cfcd7eac456fc413af9877e0a6829b372e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 402, "end_char_idx": 487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06ee30e1-d439-4efe-a16d-c86c9ac337f8": {"__data__": {"id_": "06ee30e1-d439-4efe-a16d-c86c9ac337f8", "embedding": null, "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "741ae356-8ec9-424d-9ae8-43b6aef35994", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9501df4e5fb4e7a6f9d119fa34ae2d5f8b42ae1f7d5ea9e1ef4645f2edcec3ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15361238-30a2-4022-8063-38fbc1c9c87b", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. "}, "hash": "ea2bf3e4d99597e9b345316a127b39e0af5929857561184162f1a2f25d471402", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 487, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15361238-30a2-4022-8063-38fbc1c9c87b": {"__data__": {"id_": "15361238-30a2-4022-8063-38fbc1c9c87b", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06ee30e1-d439-4efe-a16d-c86c9ac337f8", "node_type": "1", "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eba767ab8322376dd083c87e4bb5de055aa3d3200fbda55a79b9713cd7123471", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faad9df0-f4b2-4868-bd75-baf6cf4887ee", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. "}, "hash": "37f8d7414aa5d9ccf4864ae1c5b068302fc7b8719e23a1a38ca35c8c9b64f15b", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "start_char_idx": 644, "end_char_idx": 846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faad9df0-f4b2-4868-bd75-baf6cf4887ee": {"__data__": {"id_": "faad9df0-f4b2-4868-bd75-baf6cf4887ee", "embedding": null, "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15361238-30a2-4022-8063-38fbc1c9c87b", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "original_text": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b21c02f27370bf6ba7d4ae87142d3da1ce5453c36ffa140f7fa64de7565eebf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "554c6189-2850-4e44-ad84-62cb17888a5f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n"}, "hash": "b1e42b2310901517b6f95d7fd1967a2a0eb8cd9eb97dd632118e3c6df560b522", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "start_char_idx": 846, "end_char_idx": 1142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "554c6189-2850-4e44-ad84-62cb17888a5f": {"__data__": {"id_": "554c6189-2850-4e44-ad84-62cb17888a5f", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faad9df0-f4b2-4868-bd75-baf6cf4887ee", "node_type": "1", "metadata": {"window": "Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "original_text": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fabb35417f06cf0f655f7b4686565fc5b635224ddb14c726e15f35013d4148a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4108abc1-9c86-44d1-a5c4-8ba7a975a421", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. "}, "hash": "55bad5dc867b5fae576628ed4e5566782825ae2f131bb9254c1edcf78aa37116", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "start_char_idx": 1142, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4108abc1-9c86-44d1-a5c4-8ba7a975a421": {"__data__": {"id_": "4108abc1-9c86-44d1-a5c4-8ba7a975a421", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "554c6189-2850-4e44-ad84-62cb17888a5f", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "original_text": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d490ec101fafb0850133e2fd244e9a09aa876385aca056af7cbf6f2afa95463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31f246aa-6b36-4d79-90bc-a2ec63eba0b8", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. "}, "hash": "5830778ef4383dcaaec588fc5aea0fe9ea54bc337fc2313ae3df051bd20c4d6d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "start_char_idx": 1324, "end_char_idx": 1630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31f246aa-6b36-4d79-90bc-a2ec63eba0b8": {"__data__": {"id_": "31f246aa-6b36-4d79-90bc-a2ec63eba0b8", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4108abc1-9c86-44d1-a5c4-8ba7a975a421", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements, Turkey highly inflationary impact and LIFO expense (credit) are excluded because the Company cannot\ncontrol the amounts recognized or timing of these items.  Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "236af5d7747c173cbfa0e646a881ba1b011d2043b59c8435589883fba6e96fac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47c527b8-43af-451e-b533-6025a5a94ee9", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. "}, "hash": "664f5e7b59affaf6479fa481267d67b2cbeba7366652c50a379d7b93cb5d5627", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "start_char_idx": 1630, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47c527b8-43af-451e-b533-6025a5a94ee9": {"__data__": {"id_": "47c527b8-43af-451e-b533-6025a5a94ee9", "embedding": null, "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31f246aa-6b36-4d79-90bc-a2ec63eba0b8", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement\nof lawsuits that have been filed against brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in\nconcert with others, took improper actions to delay or prevent generic drugs from entering the market.  LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89a9e93b0be11ba71b5f1dd6af4b3aec4224095ce00bebd708368fb295b894e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "096e3de6-231e-44ff-aa56-12e0d56fb2be", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. "}, "hash": "301fe42dced7e28ba97b165e6bdeeaaec78ca07adf422b40055b801af168ad6a", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "start_char_idx": 1726, "end_char_idx": 1887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "096e3de6-231e-44ff-aa56-12e0d56fb2be": {"__data__": {"id_": "096e3de6-231e-44ff-aa56-12e0d56fb2be", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47c527b8-43af-451e-b533-6025a5a94ee9", "node_type": "1", "metadata": {"window": "LIFO expense (credit)\nis affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by\nmarket and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8c34d17305cd2b8f57b036cbb89766240caef66757058fdef058f2c81797f0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c2464b8-5f35-4ecc-9a32-26023c21c13b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n"}, "hash": "4d1cd2a41e3b5ceef60df2fac5a78626bc76e4b90eda2d6dc41a1ae2676be0b2", "class_name": "RelatedNodeInfo"}}, "text": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "start_char_idx": 1887, "end_char_idx": 2024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c2464b8-5f35-4ecc-9a32-26023c21c13b": {"__data__": {"id_": "1c2464b8-5f35-4ecc-9a32-26023c21c13b", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "096e3de6-231e-44ff-aa56-12e0d56fb2be", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization; litigation and opioid-related expenses; acquisition,\nintegration and restructuring expenses; and impairment of assets.  Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c37ba936d44b354b1e041b67e68b200fe206f9bc4b29cf7dc966a20f7b36a33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "10bf1ce9edab124b97298467d6d1ff67cd143777174c4cc101f14be8fb1e1a1e", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "start_char_idx": 2024, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b": {"__data__": {"id_": "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c2464b8-5f35-4ecc-9a32-26023c21c13b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted\noperating expenses to total revenue.  Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db6da65d2a7376704dc2ecd2841813ddcb7f8c06ce7984d807ab2e04129ff81a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa33bccb-7133-4233-8e9a-ec32d6a92ece", "node_type": "1", "metadata": {"window": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "e98a83ebc50711e3eb5e1f83fe149de7f08d3760914bea297585fcea12551dfb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 2304, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa33bccb-7133-4233-8e9a-ec32d6a92ece": {"__data__": {"id_": "aa33bccb-7133-4233-8e9a-ec32d6a92ece", "embedding": null, "metadata": {"window": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item\nand does not reflect the operating performance of the acquired companies.  We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e92f616f1f1628b39fd0ac7e643cda92ab7cdeb4e444589f895ab56733937e9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2725962-e0a5-4d0b-a448-22e8dbd8c38e", "node_type": "1", "metadata": {"window": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "a96e19e7622c605ce8d6710b0c18e31ba2707bd48cd52128283fb9cd167f751d", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 2553, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2725962-e0a5-4d0b-a448-22e8dbd8c38e": {"__data__": {"id_": "a2725962-e0a5-4d0b-a448-22e8dbd8c38e", "embedding": null, "metadata": {"window": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa33bccb-7133-4233-8e9a-ec32d6a92ece", "node_type": "1", "metadata": {"window": "We exclude acquisition, integration and\nrestructuring expenses that relate to unpredictable and/or non-recurring business restructuring.  We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ec86d156ddd811b9940c52c7e59558bd9816353ff212c7f99db30ec681879f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1f418b5-3ddb-43ca-a856-50c12484f786", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "58c0e6dbf098995e07f4d69b7b888ef1d1279b3738ffe3c0f072b4cccf05ba7f", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 2646, "end_char_idx": 2893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1f418b5-3ddb-43ca-a856-50c12484f786": {"__data__": {"id_": "d1f418b5-3ddb-43ca-a856-50c12484f786", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2725962-e0a5-4d0b-a448-22e8dbd8c38e", "node_type": "1", "metadata": {"window": "We exclude the amount of\nlitigation and opioid-related expenses, and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "888bdfb39eaece7229d23579a4bb2e10d2e790834822c9f1be84c0eed59442cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7a211ee-fe01-48c4-8e4b-36c43305c716", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. "}, "hash": "584de5424e9b796b039e9bc1891374d00e51da57e2bd57a780b32913f4d8fc45", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 2893, "end_char_idx": 3098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7a211ee-fe01-48c4-8e4b-36c43305c716": {"__data__": {"id_": "e7a211ee-fe01-48c4-8e4b-36c43305c716", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1f418b5-3ddb-43ca-a856-50c12484f786", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2735466ad5d540de6fead684e5826bb510fbae13d7c26573388f9a7b38b319ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "46818fc0cbd0ed9cf81f4442ff5645a6a57b15eee86bb816d39eef59eb4712b5", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "start_char_idx": 3098, "end_char_idx": 3387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8": {"__data__": {"id_": "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7a211ee-fe01-48c4-8e4b-36c43305c716", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc85d25551da7c37c499138b7d8dbae54d3bfb274bf432c9a4e8d4f4c00c20d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69a61cf-d15a-4303-b547-4285c7ce4d92", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. "}, "hash": "fa937ca376636fba13efd6f853a407032d46e26d285dbb06167b9cf81f41995e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 3387, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69a61cf-d15a-4303-b547-4285c7ce4d92": {"__data__": {"id_": "b69a61cf-d15a-4303-b547-4285c7ce4d92", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ca3b074fdfdcb64330ee3fb0a2bb52149d09f0929c50d903e7babc9abaa2520", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217089ee-4d2f-4aaa-869b-903f9e838382", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "b4ee5c019f513a353625645025c7f00de0b4f75367274558f39c13afc823346b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "start_char_idx": 3552, "end_char_idx": 3741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217089ee-4d2f-4aaa-869b-903f9e838382": {"__data__": {"id_": "217089ee-4d2f-4aaa-869b-903f9e838382", "embedding": null, "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69a61cf-d15a-4303-b547-4285c7ce4d92", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c446eee111dc5a359aa610dd47a2fbf9b2d07d3c624cdfeba1a522ec0d900e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "e63053b880e27a9ac424e8e5913f62c369fef6c62a373169a553747b48463f17", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 3741, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03": {"__data__": {"id_": "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217089ee-4d2f-4aaa-869b-903f9e838382", "node_type": "1", "metadata": {"window": "In addition, the recovery of a non-\ncustomer note receivable and the gain (loss) on the currency remeasurement of the deferred tax asset relating to Swiss tax\nreform are excluded from adjusted income before income taxes because these amounts are unusual, non-operating, and\nnon-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7481e5baa7e6dbd45c9e3592818c9b5748bf7225a22cdc83d2df9d522e9a6a24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a79b6b4a-b8e1-4c10-b652-77d434623ffb", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. "}, "hash": "e4cbc2ee1c29a0be474e0015fc80f68ad10f23469596936ea90149d3dd47f3aa", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4014, "end_char_idx": 4252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a79b6b4a-b8e1-4c10-b652-77d434623ffb": {"__data__": {"id_": "a79b6b4a-b8e1-4c10-b652-77d434623ffb", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad886a2f18a1fcb0553b19feba18be35a2c82b76fc6212f33f0d4ede6a4eaebc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e2ae5f-196a-4e8f-aba6-2b34d2513625", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. "}, "hash": "dff5f90dba04094dd774915664cc21bc2123eee23844d6bc97500193134deed5", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "start_char_idx": 4252, "end_char_idx": 4455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e2ae5f-196a-4e8f-aba6-2b34d2513625": {"__data__": {"id_": "a3e2ae5f-196a-4e8f-aba6-2b34d2513625", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a79b6b4a-b8e1-4c10-b652-77d434623ffb", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense by adjusted income before income taxes.  Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69376916062b78ecaa5019dc50c84991e8c57ad57e6bcb29b825fbc98f339149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n"}, "hash": "0fb5568d84aad0e806260b8bdfdd8116b116acb5a52c66d37282fc3e80b35a58", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "start_char_idx": 4455, "end_char_idx": 4620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0": {"__data__": {"id_": "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e2ae5f-196a-4e8f-aba6-2b34d2513625", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it presents an effective tax rate that does not reflect unusual, non-operating, unpredictable, non-\nrecurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33d711faea4a820a3f86c999883c5624a582ccf7b4360f9f97d2da85ebab5d43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c87766f-ea6c-4f26-a84c-c6c825e1be3f", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "6ba02cdd199e2e3f707e9de134b1123dfde964bc7998d7f1f889847c0433088f", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "start_char_idx": 4620, "end_char_idx": 4864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c87766f-ea6c-4f26-a84c-c6c825e1be3f": {"__data__": {"id_": "5c87766f-ea6c-4f26-a84c-c6c825e1be3f", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ae12d35cb34e3ee828c384401e80d972e7325e0cc77c0823f9d4524ea77fd14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "2cb61325f1fe1775947e71a3f2521b04173e8cd1de0a8622e3cdfc3f5885c3a0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 4864, "end_char_idx": 5078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8": {"__data__": {"id_": "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c87766f-ea6c-4f26-a84c-c6c825e1be3f", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three months\nended December 31, 2021 are also excluded from adjusted income tax expense.  Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "206edfcf2f6e565cdfe18af73ebbf7966663509886192800dd6c0295a745900b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c701598-9bfa-4477-a0e8-c5fd4312b091", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "18"}, "hash": "d79fee273c1bd773efe76d04b6f9b7e11b7fdeef4a6d827185fe98ae1e040f57", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 5078, "end_char_idx": 5249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c701598-9bfa-4477-a0e8-c5fd4312b091": {"__data__": {"id_": "5c701598-9bfa-4477-a0e8-c5fd4312b091", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9708084f2bbd5082b2d4769602fa43bb198fe3aa2eba52b3876e74d975cb40b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax\nreform in Switzerland are excluded from adjusted income tax expense for the three months ended December 31, 2022 and\n2021.  Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "596a1d070e4875f9479f0e42f49d21c200a555483f4fe10dec75254ed17a4262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d983686f-ceac-4f73-b65f-967f45efa739", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "670939106465b7e42d5b66561c90c543936a54ec30502a5937cd3761ec865bb7", "class_name": "RelatedNodeInfo"}}, "text": "18", "start_char_idx": 5249, "end_char_idx": 5251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d983686f-ceac-4f73-b65f-967f45efa739": {"__data__": {"id_": "d983686f-ceac-4f73-b65f-967f45efa739", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c701598-9bfa-4477-a0e8-c5fd4312b091", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate\nthe Company\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash\nin nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ad787055e67b195fd8f6ac621e8dda0e4baa880859f8a9078bb96caf3d6d4e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "36dd7b6def411c91218625fa7271034d64ac1b36ed5ca652c9c26b6dcb5c9898", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 0, "end_char_idx": 185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801": {"__data__": {"id_": "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d983686f-ceac-4f73-b65f-967f45efa739", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f8e7828c67c7c261927cd6d6b136a733f3c8cc0f6e5a7a8c92f745d8b161bcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dad915d-60e4-40f6-bd62-46be6b5bbbc2", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "46cfc4f140b56829b10289f068bc76d7f9e77c6a6a5594f79648a1e10cd2884c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 185, "end_char_idx": 429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dad915d-60e4-40f6-bd62-46be6b5bbbc2": {"__data__": {"id_": "5dad915d-60e4-40f6-bd62-46be6b5bbbc2", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d56e61c0a59ab16de99dfd133ec009c1442bd5a6521a49d6fb459a27265e4be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c591a12-3228-46d0-a3df-deebf0ca250c", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. "}, "hash": "70e164dc4fe3ad7c3d7612cbe4897e9af5a866375e3c462c4b743191e813439b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 429, "end_char_idx": 1049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c591a12-3228-46d0-a3df-deebf0ca250c": {"__data__": {"id_": "0c591a12-3228-46d0-a3df-deebf0ca250c", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dad915d-60e4-40f6-bd62-46be6b5bbbc2", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecd962e2b339c067c9fda54552bfd7378ee809b9f28f7450de412cbf59635759", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2b870f8-2e84-4dc6-bc88-60fba1cdab90", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n"}, "hash": "1439aeceeed5dd1c479b36c965430bf6f2423c52d1c5e59b2525a2d30e795a07", "class_name": "RelatedNodeInfo"}}, "text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "start_char_idx": 1049, "end_char_idx": 1424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2b870f8-2e84-4dc6-bc88-60fba1cdab90": {"__data__": {"id_": "a2b870f8-2e84-4dc6-bc88-60fba1cdab90", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c591a12-3228-46d0-a3df-deebf0ca250c", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "original_text": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "417bed74c186f4dcdc2b25b460a6b4890235e3bda4e7711189e5c1f63f958d7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "aa8c902d0c72f182511f02051c2dfe3257abf9ad1a5289089839977a286dba21", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "start_char_idx": 1424, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef": {"__data__": {"id_": "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2b870f8-2e84-4dc6-bc88-60fba1cdab90", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3c8969dffffdd25b6804a4ede7dd49f622755c19a9fbb0e6f640d7e45a09c62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. "}, "hash": "9b0fc5b793d052b48dca9142924cfd84dfff5ca31675c8254edbe978380b9690", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 1778, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2": {"__data__": {"id_": "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2", "embedding": null, "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1beb5cc688ebdf2878b0e4475549be8bd3fc856090e43675de8bf56edb556586", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1e1e6c7-caca-4a49-8e71-ba108a0a4666", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n"}, "hash": "84a6e57ed8fae85fdcbd725efdc5c875e4e3729b470c8d7c8138b90aceaeb19a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "start_char_idx": 2051, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1e1e6c7-caca-4a49-8e71-ba108a0a4666": {"__data__": {"id_": "f1e1e6c7-caca-4a49-8e71-ba108a0a4666", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2", "node_type": "1", "metadata": {"window": "In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share.  Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a465ef59859735b29b4d836217e5111f5e91de22fde09014f1f9715be488aab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb273229-51cd-4ed0-8402-e4ca99af5659", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. "}, "hash": "8bc950a7a25736fcb6528e75b16f4910b18b70b358d118d05b43127d7cb1b426", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "start_char_idx": 2289, "end_char_idx": 2585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb273229-51cd-4ed0-8402-e4ca99af5659": {"__data__": {"id_": "eb273229-51cd-4ed0-8402-e4ca99af5659", "embedding": null, "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1e1e6c7-caca-4a49-8e71-ba108a0a4666", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it eliminates\nthe per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our\nongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash\nnature.\n Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "322363593238bcf51f7ca6dd71312ed763a64a358ac8df947289d1e93ec9a14d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67ffbe03-8c49-4c3b-a433-47dd989d9f97", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "349d9bb03743266e35828db4429b39ef50476fe87aab658183faa8c6a7415b18", "class_name": "RelatedNodeInfo"}}, "text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "start_char_idx": 2585, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67ffbe03-8c49-4c3b-a433-47dd989d9f97": {"__data__": {"id_": "67ffbe03-8c49-4c3b-a433-47dd989d9f97", "embedding": null, "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb273229-51cd-4ed0-8402-e4ca99af5659", "node_type": "1", "metadata": {"window": "Adjusted Free Cash Flow: Adjusted free cash flow is a non-GAAP financial measure defined as net cash provided by operating\nactivities, excluding significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44aeaf7a992e132f101328215bda72251a734a98710457f431a5ac4245340b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43d09fe2-749c-4118-afb9-5a6ec11afc5a", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. "}, "hash": "71aa5ec44cc679bb19f32057ec4dbc8dc26add920d385a7973fbae418f1508b8", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 2739, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43d09fe2-749c-4118-afb9-5a6ec11afc5a": {"__data__": {"id_": "43d09fe2-749c-4118-afb9-5a6ec11afc5a", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67ffbe03-8c49-4c3b-a433-47dd989d9f97", "node_type": "1", "metadata": {"window": "Adjusted free cash flow is used internally by management for measuring operating cash flow generation\nand setting performance targets and has historically been used as one of the means of providing guidance on possible future\ncash flows.  The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29dfe696d3c1f8104386fc07b148214b28d1c1a53cb66511f1e9719f41a96df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6e64b94-7721-4ae6-af8b-22a7ff30243a", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n"}, "hash": "f88cff210f6a2f9e85b4dbe68f37a342219db819007d1c906542fdb742147fc3", "class_name": "RelatedNodeInfo"}}, "text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "start_char_idx": 2894, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6e64b94-7721-4ae6-af8b-22a7ff30243a": {"__data__": {"id_": "a6e64b94-7721-4ae6-af8b-22a7ff30243a", "embedding": null, "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43d09fe2-749c-4118-afb9-5a6ec11afc5a", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP basis for free cash flow because the timing\nand amount of favorable and unfavorable settlements excluded from this metric, the probable significance of which cannot\nbe determined, are unavailable and cannot be reasonably estimated.\n The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "original_text": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "738ac991236adbb6786ee634982d1e0698ce492c3deb994327ae3a91065fa893", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe8ceae-8693-4c3a-adc3-1bc2bf417d78", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "6e6b38b113b51a1c0a1612fffc5e4b00f3e75ceb6105a4234efb27e73081a664", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "start_char_idx": 3071, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efe8ceae-8693-4c3a-adc3-1bc2bf417d78": {"__data__": {"id_": "efe8ceae-8693-4c3a-adc3-1bc2bf417d78", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6e64b94-7721-4ae6-af8b-22a7ff30243a", "node_type": "1", "metadata": {"window": "The Company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45e09c0738ea0630a112da23762d094efe3bb4edcbbdba4b9424d581aeea2e74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7891970-599d-40a6-bfd5-1006ce03b4a8", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. "}, "hash": "3a3bf888d954f290048bc2a988c7c905ded0128a0969730f17a2078759dafb8a", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 3227, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7891970-599d-40a6-bfd5-1006ce03b4a8": {"__data__": {"id_": "c7891970-599d-40a6-bfd5-1006ce03b4a8", "embedding": null, "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe8ceae-8693-4c3a-adc3-1bc2bf417d78", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c2af7b93186b35fc0e86a591a232f0a8d5f651a866fc99de715776057b5b43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b39c5648-72bf-401f-9f88-c421860a6ebe", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. "}, "hash": "0825293a02c35b7230580b9f8496fdab81514dfa01ad07112c085cb17a52e5e3", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "start_char_idx": 3677, "end_char_idx": 3913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b39c5648-72bf-401f-9f88-c421860a6ebe": {"__data__": {"id_": "b39c5648-72bf-401f-9f88-c421860a6ebe", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7891970-599d-40a6-bfd5-1006ce03b4a8", "node_type": "1", "metadata": {"window": "The Company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "505e76fe6e09a3b850397dbcf63eae5fe01425c76983ac62357cada47982b1d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffba1e90-2d40-4dbb-9810-a5a52c599848", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n"}, "hash": "0587b6504624e0c983ba310e6715af9f195dfd542295893ea6bc644b1ced0ca5", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "start_char_idx": 3913, "end_char_idx": 4229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffba1e90-2d40-4dbb-9810-a5a52c599848": {"__data__": {"id_": "ffba1e90-2d40-4dbb-9810-a5a52c599848", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b39c5648-72bf-401f-9f88-c421860a6ebe", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a48a3102e0d7460dc39c972eab0f7adf0cde7378846de98efb839069a19d187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb468a74-a11a-4bc1-acac-7c16a44523c1", "node_type": "1", "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19"}, "hash": "26d347048865d58139b7a19392b40bb5e95204ade48fc31cd10f7393842148cb", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "start_char_idx": 4229, "end_char_idx": 4413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb468a74-a11a-4bc1-acac-7c16a44523c1": {"__data__": {"id_": "bb468a74-a11a-4bc1-acac-7c16a44523c1", "embedding": null, "metadata": {"window": "The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a19cc2ef787982e35c1dca3006f96a8fddf4aef6d8a09562a8d5ae253fbf57", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffba1e90-2d40-4dbb-9810-a5a52c599848", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2023 guidance for diluted earnings per share, operating income,\neffective income tax rate, and free cash flows that excludes the same or similar items as those that are excluded from the historical\nnon-GAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  The Company does not provide forward looking guidance on a GAAP\nbasis for such metrics because certain financial information, the probable significance of which cannot be determined, is not\navailable and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon the future inflation or\ndeflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-related intangibles\namortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.  Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "original_text": "Similarly, the timing\nand amount of favorable and unfavorable settlements, the probable significance of which cannot be determined, are unavailable\nand cannot be reasonably estimated.\n", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "581deaed45e333c07b8ab82614a7e5f16a78d613879cdca3a8e1900d3e6fd2ea", "class_name": "RelatedNodeInfo"}}, "text": "Bennett S. Murphy \nSenior Vice Pr esident, Head o f Investor Relations and T reasur y \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n19", "start_char_idx": 4413, "end_char_idx": 4586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"15b1e7c0-a55a-4ee8-a86a-b667818374bb": {"doc_hash": "fdcdfe33a68e4c7dc9ed85e20f2936e213e042bbee8d27e11846a3ee2c884624", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "54cda69d-0b0f-45ee-923d-47d2adac06c5": {"doc_hash": "23b2107e1546683e1c220e88529b1d3712b449a62056b72020d358b2b4a2a8b0", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "4ebd334f-e3ad-4f56-93ed-d98766d8642f": {"doc_hash": "6a99ae9ed45fcca00df9cd217fae03b30368a20d14c30f21c50f6db8de2f8235", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "44bfbd15-d9fd-49fe-930b-71feffa4192f": {"doc_hash": "d3f98256809f8b900bdc7d028102790e42fec4fdffc1fe40442dc83b7eb89de1", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82": {"doc_hash": "c7820a68ee8bc54e2cf169145281ce36f3d9c4b0338014d733b79659186fed2b", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b": {"doc_hash": "a7fb47f8011a113fd8dbf51d7de39490c1ed23f4784ccfe44a12da9d65bb9052", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8": {"doc_hash": "7991863b650730eb42d9c4a36c01bb8ca14eb19567d1f6e37ef66f125f15049d", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd": {"doc_hash": "c2b6e1941e01e3abd4006b98e7d55d3edffe777b231e5d13fba9bdb8c9be1031", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "896cd2e8-5806-40fd-8f0a-ea2628e6a024": {"doc_hash": "479dd8e88c671e1d12d93b587283a3466edf1342b6e191b42c17f7b17a9c5d38", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825": {"doc_hash": "6fafd6261fe518b58f7733ef259673d2b0f44239ddfbba30a2cc7c695ceb424b", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "6557afe0-45c2-40f3-b090-ebe21613a7f0": {"doc_hash": "23058ad90fa3bef0e87204878fa23a104ce6a73ee6347fc45b4c1b68f66716a2", "ref_doc_id": "6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e"}, "c7987cd0-7555-4873-9819-61f60c9df33c": {"doc_hash": "3016fe7d4f4cef6cb10a568b004931b1dd3b2b5a836acc4ea0381f78816cd907", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "2c99447e-71b3-45a1-9554-0d2484aa9151": {"doc_hash": "66c168e343049991ec87fcf004b3261d6fe76c480726aa7f512160dfe527a7c9", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "31de26dc-cb4a-4883-b3a2-e16b20fdfb68": {"doc_hash": "b1cf38a97d7d63ba4ab49306215c3fae868bef0810b19a4e0d5c8f3472351662", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "e3157dac-10c8-4fae-aee2-d48e1e5f305a": {"doc_hash": "1bd43759e24e4af4db69bb851f5b8520753a8ec7f6f3af792c3357c9a739ecd3", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "767585d5-7f82-4157-b1b2-708bb2abe359": {"doc_hash": "8991bd2d0e3caa795b7c2d7d56c2dd56d68983f63ee08689c43b1379eae7cbe4", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "2a451e02-04ec-4953-b340-52c537c67c07": {"doc_hash": "17657e427acb2c95f0d76110c79835c99364c32122da529b83ea3a110132ae45", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "fde71149-4758-4ef5-a17e-473523a42c48": {"doc_hash": "13cd48437bb3a797a52777863dac95c75bea07fc0da251bd7014b2e5aa1d6209", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11": {"doc_hash": "4511e8ff6657786fd325e8fb34727a8abeb7ec8534296fb6183458eb2d957bc7", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "197ac244-55f8-4e3a-a0d0-b8d9653882b0": {"doc_hash": "b20e50b39a829fd72723a72b9e2d29ed6217c5ce527b8f91b11c63b8b2759f0e", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "08e411bd-c1b8-42af-8cdf-fcd12868f0fd": {"doc_hash": "81bb671add9625518267ba734a7de632168223b7dcb22e1e9497b02e6b80526d", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "15bfd802-87f2-467e-8b79-664897e53bbe": {"doc_hash": "77c6b1a0192d8f1449f913d42daf3730ad49503083929c22bf83520c8328336b", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "32d63ee3-d045-493a-967d-7eaef97aac9b": {"doc_hash": "df0c177eac75eca59c3cb98002ac7859d7e7fcf4f54f930cf9850f2e9608f2c4", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "403b7d97-859c-4e07-8ed0-473859727237": {"doc_hash": "9636497c2f9b3a2a13ddee531bb9eadc1a2a02c13dcb744bbb9a0925158db541", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "cfbcedca-4a9d-4d76-b976-b7c2c89d412d": {"doc_hash": "ff099fc58391f31fcd49c141071c03a9b51649f6ecd8acc1c86dad63d11708ab", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "5b4ca3ab-f6d5-4bff-9728-836b33105f44": {"doc_hash": "a74d65801e4d7365963d005c41bd61642481537ad5caedd757edb7c2281a1060", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "1057aad3-cf94-4132-96f7-2b7f3a71dfcf": {"doc_hash": "fd3d75352046480420116507b5332c769e30430bd2f9128aa2c4ab839eaed561", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "34fbe4fb-7166-4810-9b53-a414d785e719": {"doc_hash": "dc0a91161cf4c903fb9f349859f7b8482f8475d36d79c68df950d5ea28258224", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "939fcbbe-9790-411a-9a9d-c563becca4a4": {"doc_hash": "ac579aec3389fcaac2a5d8ef55b4a31e02f5c6b225634bb828e6fadfb48a9981", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "11514d0e-faa1-4480-972b-8cf0cbee0627": {"doc_hash": "78efc5ffdd1d3cf1d4a7b56783b117d50845b105a1c754c21422c8f22a0c164b", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "665794a7-3fe6-4c9d-a59d-6b18b85488e7": {"doc_hash": "f90be23fdd9ebb8e94efb130f457f41269f65b2af08d93c32cb787010b243bde", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c": {"doc_hash": "91b17daa7c79ef8168f7c6de00698ad4fa28614d4764f2b722942db956d85ad8", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "a416c874-637a-48ba-9b92-9986d737a006": {"doc_hash": "bc112efb6801b1e92dd6a5a1d3668c4a4bffd89432ff9dd611d666257966d062", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "dd1355bd-210f-4697-8a22-c1c6a91d5080": {"doc_hash": "c0fcdc515814018c7ea5ea770d6d380a5dd9ca415226d183f6701fb1aac97002", "ref_doc_id": "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a"}, "fe5490f3-fe33-448a-bbbe-58972cff51a0": {"doc_hash": "5d2e497d64696b0b336f3e9f5e8443ab6198f2ad99e43763caaf0f909bd605cf", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "4d7fd800-40a4-4dff-8b8a-cb15debe0045": {"doc_hash": "c9dbc66b150604bdb1c33d4b21516056eef50a2f4837dda413dcb74849f3bf1c", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "56a079b3-002e-4f90-aca4-bf5cfe721d08": {"doc_hash": "21f77bfa276a884d1a6a9c21b69eb89593dc96f19e711bdfd0c00d64a494948a", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "fce4c8c4-e877-495e-98a8-535098a314b5": {"doc_hash": "f667ea8e04e50049ea8a4368dbbee8d626c5e29cbea12b0c8ed9d7285a69b19d", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "70b5da4a-8e39-4bd3-a8fc-984101b0b5de": {"doc_hash": "149d42e422a451b7c62cce7bdfbdcf94cec0c4d8a9ff27cf75094806f156fffb", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "afe396e1-7f48-43be-83c2-9358273888d0": {"doc_hash": "601f8d056dc04030af85d42282cc7a17517b1456c1039fdd775571cef66452fd", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "a991c8ad-d945-46b0-b02d-b0d84e37e676": {"doc_hash": "8ab099f40f2bb14364d7d5d0d78884d5b06b006cb2bc118f55ca1e3df70efc0f", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "c274179a-5980-4e78-931c-637a694a0991": {"doc_hash": "6e262f4a3694377f0d1b87430bd9a5877ec56a96bffb2cf534f9f629a06f1253", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3": {"doc_hash": "358de3b954308c41c021f85065c0014bcb9c8caed0a41e928122c4baaeec6f0d", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "5ecec636-a153-4055-a531-c434d1d9babf": {"doc_hash": "ab201ff951aa00c00f1e3b569c9fe264a004ea066283f6d0862c8c17e746dc20", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "b5060665-b5e1-4ccc-a22d-0ab74b811c83": {"doc_hash": "9adcec549818057ec8f2a4d69c12831cfeaa386d2065d564f0c4d53a4ec0a25f", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "2737015e-5317-48ac-85d1-7d625236503c": {"doc_hash": "4509928b25146030e4c5cf004de8b4df411d9ea7289338e1a7dcc08457869b73", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "e75a9f66-3540-4a3e-b1dc-f4447912c6d9": {"doc_hash": "9c59ef741d2b039b3f599ff1f7ad07f5fa34eec7e39214e9798189c3fab1cef8", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "13e21864-44de-45cf-8a58-ee90d747b90a": {"doc_hash": "2dc3e7b2c9bb2d88a1582f252ecfa0a4e3c29dada6d0a51788bb5c59efc8c597", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "8c8443f2-d873-4e0f-9c93-a78e8d953a84": {"doc_hash": "e996b320efbfaf1abb3ce64b93e66cf53b3335c92d1a69f7ed4af598e3609d59", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "9dbe802e-d65f-4f23-a031-6e155663469c": {"doc_hash": "8af1f9fa9f85215de68aff56ed35be8719fc35ea864c65c551a3f5b74fce0325", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "757a4747-4c4c-4185-9d13-88424a46b17d": {"doc_hash": "089a9f21401b3576f8e18006f8b27494a8bff8cb395cd968c19c369657d6188b", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "c8478656-1f44-4cd0-9e72-89bf3bfc505d": {"doc_hash": "3f6aca4ed30ec8e8cc06c4b5b3c457b0544889265ae98b0761ea01378e22bf8c", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "a724bed0-253a-471b-84fa-4116e09c3c21": {"doc_hash": "7db05af9cb641db3377057bcab9734a7dc53d7767b7bdb58b6ac88f021fbdfe8", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "0de87473-b6b1-4fff-947f-b22f5a626084": {"doc_hash": "e9a70fa78382f01a1a45dcab0908956261710397ab8f241ced3026e984117a9d", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "8a4cda22-09ea-4afc-8111-58c1f73c128b": {"doc_hash": "5c4893f63154eb2b6f801267ccfefe9b6b01c0073db013956833951c0e739f62", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "ff2bdccf-7052-419f-8f28-448d12f9b071": {"doc_hash": "b8b1e55b5bf5ce64414869d7fdb0fa928ab5e02a8da8c0d767e5beefa5cbcc42", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "bb04fb34-3d5b-483b-b74a-cf239a7b1183": {"doc_hash": "6209355b2c41a9d064835432dca7dc6b471a08fe457832ef13038f0a304a7f4e", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "605f6271-96d7-46fa-b2fd-62f66077e314": {"doc_hash": "1fce2579bb6e735e92fa9e7dabca250657cafced6c24c4706d706624cf55513e", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "95e6671c-7b31-4fb4-988c-2d2c0049d613": {"doc_hash": "11b8d3f3ed3c1fb0f0d261b2a042aa596317f49fbdeac748c604cbcb3c056264", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "5763c603-49dc-4fa9-9c01-988b62fc461f": {"doc_hash": "48c65f120e21be06f59a6d1df6c67793c9c6b83b3a1547cfced4075cd80b5019", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "3959970a-2948-4214-9ddb-880e8784849a": {"doc_hash": "373f884c5990ae1de4bc6650c38c017366b5a28529896443784a7829debe9f50", "ref_doc_id": "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7"}, "25e0ea99-2c72-4f42-bb25-a759f249b9ae": {"doc_hash": "30cc956f74bf29bde0f8dfe5f15c1473163f7b54062a253729c2794f2d7a13da", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "3e2dcd19-e214-4fd8-be65-a86d238f33a1": {"doc_hash": "1c5aa13158c1abc7fe72e1dcbbfcb30a67784dec71f40e851ae4aa7818153e48", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "51f9f617-144b-4da9-96ad-55f82d55747d": {"doc_hash": "34e10cc4d271426b07e7dbe2b195a0a3535f8f7782bff50d493d967ab43e654b", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "bb9623f4-cf1b-41ab-8f5f-c4c952d98808": {"doc_hash": "652cc63ed673e5829d1d70adf6f3f4875d826f1182439cd26e5d810d29582d73", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "eca8983b-f1bd-4232-8306-6ef8d05c1e02": {"doc_hash": "6212d6c5a933c3dc43e09f67493278f874f377e99ad036c47bc007fc780683cc", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "345eacb6-1636-40f1-9fcf-a96e24fa245f": {"doc_hash": "7fd9b1e0501793fc1a96b15f8e34aef6bd21185c44ed77fa7eef4bc1e91a0bba", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "eb2daec6-e492-4bbe-9973-da6f663cfe74": {"doc_hash": "7994ec0bdc9e96de913301945e85773821cc58478a2ab646cef403b4ef1282d0", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "21028618-b0b3-4dd5-b9eb-c3e34ef45557": {"doc_hash": "fae78e2b2fcb9cc155dab58061541fbdd0ab89d0424bfd2d2618fc26ed1cdbeb", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "291e11dc-f5a5-406a-a269-635a457c2305": {"doc_hash": "d39741928a6200ebc867c8a3871408c72bf411cf479288b41011dbe5b259dde3", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "db832058-5154-4ccf-9031-5c822af6071d": {"doc_hash": "9a70e3c978ca3c4799c33498f451de3c0c287fff39244a00d0d85394fe735f6f", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "20e90243-8f48-4f68-855e-4ba29f1f1baa": {"doc_hash": "e6b200f79c19f010eb9c6a551009229d12db333c19566384d0dbb40550690161", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "48eb52d4-fd32-47d3-8875-f9e8c471d698": {"doc_hash": "f3d479d625974f72abb555e93b7d5cd6e352be7a0c6d8d1f817a9a4598d224db", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "21172005-daa3-4378-826c-8ec471f82e70": {"doc_hash": "82096129b874ce31794029337fe12c3f3884ee8d17a54ca6dbe6ddd85544fb0b", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "7ab02006-a659-453d-853a-0cb0e964161e": {"doc_hash": "a5ed231c0ad1734f5fa9cd2dea499bb5412653625998d729bc705c19f83c970b", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "4bb765d5-2968-499a-b58a-891d7655b3e6": {"doc_hash": "56267df12065b7c689aae680ccb018a00ec14c31d41c25d37e10c576a38ee979", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215": {"doc_hash": "8d49aca75e78aeb0842ce6efffb23b454e7f75f6f60626f8e1824d3097a346c9", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "0d5e55b6-56ad-452e-864c-b90064c7845d": {"doc_hash": "df3f6daf84d1e932f81cfef86161187317c8aa3879895c51b1a7d43e00d95e38", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "dea15763-144f-4bf3-a06c-214a7be8e21d": {"doc_hash": "f6aea733d43029e5d09ca726041f3b84e5af260dce071f37281dc7a1decd9427", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "f9102cdb-223c-4de5-b441-14db59edbb01": {"doc_hash": "b1e1e571620327ba11095f1c4674305b89dbffba41383e5f4a7522d4f3db615e", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "b77fa293-2edf-42a7-b64a-b43e887075cb": {"doc_hash": "c724b745e84cf7f2c22fd85d8da9a82c843afecce73acbb87ad9bd343f6bb3c8", "ref_doc_id": "a9f502a5-4335-49bd-8223-0791e4b172c3"}, "699349b9-f0fc-4d12-82d0-c332caefcc25": {"doc_hash": "62aa5627ee7715c0fa1ee40d332455732f00d2fae45fe70235307c6488e6c1d8", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "fdd0e06c-714e-45b2-b834-acf54caaccae": {"doc_hash": "3341a552ceafb8b79391677e829f82ef17c2e7bee459faf3cbafe58c3e825074", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "0421e8a4-2589-4bad-8fb5-68f7501bb891": {"doc_hash": "7b54ed62cbd3da2bec5d03ab316f02e81c688711a043aec9ab8a75e208dcaca5", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "494bbb25-2e97-4aa8-8c60-a6712e37df85": {"doc_hash": "836035f0f6b2794beface1853a65706e17f987796e71238827ceb3fef1e669ef", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "5e048306-925b-4ae9-8ce2-2827e4cc4c81": {"doc_hash": "4c6ad1d8559b9928657b3e370621d011a54c404dba95b4f4b31ae7cf8298bdc4", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "5a5f89d1-9384-4246-84fd-14944aaa72fe": {"doc_hash": "e32650f813542db3cddc5d9885268c96c3067f767fabee164eca7a55ff43711f", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "4d910207-a785-4cab-a84e-4ace90d34875": {"doc_hash": "b99281368efadf872fd805c010ee5f6f44d71f7371cecba97e588aac6f36696f", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5": {"doc_hash": "06ff58167dab2f038fb517b1c9a303de28ddefbd84394dd82f6694b577e8be2c", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "ccdca928-32b5-4d84-a630-c4e2d3989e9c": {"doc_hash": "e79e91f1e7b6a524b2939399c6e16f465ebaf2c3692f685d1b9d7004d9ab5f18", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "b4f77887-d0e0-43a9-bc4d-60b42a7acaae": {"doc_hash": "e62d2c2216f1c925a9fb88bd4e59b523169822db79cf7fbe14a7fc2f978b7ccd", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "f146e8cc-7eb2-4315-a6ca-f905310b9f2c": {"doc_hash": "2464494ead24bfb8d17696e8a98f1090b272f3fdb2fb4a6675637371d38367b5", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a": {"doc_hash": "9efa90ce97b1346581c2ae02c650dce1e5487edadb6a07f6dcd965eb5065d9ea", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "6f159e87-6b94-4026-8502-8926a87a351f": {"doc_hash": "b019a8761f0778d7972bf604fe56d47c5fcd87ce81b3794a7a19d2cbfe65fffe", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "e6a94759-6f4f-4d24-b44a-9ff3da919f16": {"doc_hash": "34acd4a5e8c4b6bb81028822193bcb1796cea7c1dbf74fa1f8a536bd007003d7", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "bbfaca59-780a-4316-982a-db79b85b31f7": {"doc_hash": "296b8c4d0c31ce622af3f2aad72977464207536102029b5390e41eee747505f0", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "7926e76b-afda-4f16-8805-b5a72d4cf770": {"doc_hash": "4989e117b3330d5fb6b2f3d07ed313a3a395d03d3224cd5215be4ee534bf79c1", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "2e78a047-26a7-45a1-8adb-c671cca3a18a": {"doc_hash": "0de9cb2177518bba836f75ac7cca2c085f243d0c84e8faabaa48b4898dddd38b", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "6283bb1d-fda4-4239-b923-553a3225d5a5": {"doc_hash": "236fe635eea441d0903a2bf39d2fa5d066169e2b79422796a831920a24978b49", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "6b08f357-75d3-4702-8826-f8bc86c03386": {"doc_hash": "d2174042c77f792a6cdc25b74ff5ccd1bfb8a7e67922122a3440baf299322bf5", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "9469b69f-9994-428c-96bf-48afc44fbdf1": {"doc_hash": "54c2e7fa067deb09b2b399f91fa2388810736f7d6d1cae26b37af3bd6dd8620d", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "e77e9336-dd87-4997-a87c-a7669b9ad69c": {"doc_hash": "8fc5f0d5a1a63dae7821afdf64574a9b4630c50cb1e8e5732e1d732dc402d128", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8": {"doc_hash": "90e024fd23e46f3c65db03db931f02a350956053c7a3677cf6d7c93ba6c13b9e", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "2d3ffbc3-5ed4-4d35-8367-af13dfab9320": {"doc_hash": "7c5275a5e5320ac60b1b6180dd3e2b4d37d08b5d53a388120aed84f802799ff3", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0": {"doc_hash": "b4590b3f041a9e5b0ceaf0195cdfebe0626ac20e4f86415f1847b04f28cc4ea5", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "e5af2fc8-b068-4e50-b1fc-53b902634dcf": {"doc_hash": "cd0414d7fb1742e02b18e98642851afecf31c65d15405c3775e6b1ef46f9fa6d", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "bf4fce91-76e0-4395-b5aa-a64c95c35a52": {"doc_hash": "3c8aa6f200be0ea311c74beecf8ee821be1c898de4c7822492d5b0f066c794bf", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5": {"doc_hash": "a0c9804313a93d3756c4b88dd9f3382b48ea661bc5bbaa44cb1bc648a682371e", "ref_doc_id": "af3278b2-63d4-4163-ae9b-c159922c35aa"}, "eef8b813-89ed-4245-8570-cfc722b06c59": {"doc_hash": "f059b6cc2ca835235243dca4893fc004b7797eb8dfdc0898599003afe19cb2c1", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "24829ef8-6bc6-4b34-8466-cdd0a2f17cad": {"doc_hash": "2adbe69d84c8a39538b5e64af4d6aea17584cc673a0e048aab9b6c03ebb746e2", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "74fbd71d-0b62-47b9-aa34-7d77d1dae430": {"doc_hash": "4f730ea2c20219c03014a17b9b341150a1b3e56d59834cb96067bcd82f729260", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "3e3b232b-053a-446b-95ea-a5f9af1fffd2": {"doc_hash": "d2432511464aad8c411ea314f8d7b204a4eaa5db76494b89a303396b7a00a022", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "5a622475-2df3-4c04-8bdf-508c272803fe": {"doc_hash": "5cdfc3e060630f31c7e3a0a8959abf24e224c8de1983fab6a1a4dd63d43dc67e", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "e6ec5399-f0b8-492c-bb14-cdad36aafcc7": {"doc_hash": "c95816ff7526aee970bd43d8953caa39b27391184773ad542db91c934b91f78c", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "19fba8d1-c28e-4332-991f-b426328b270a": {"doc_hash": "19e1f9fdd9fe36141be1267eb7ac0c89196c11947073e104da5d4d6a6b87480b", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "a0b92e8d-0d16-43b2-9677-6484973a13b8": {"doc_hash": "4e7616be394dbbca53fc5e96bea3f9b2b586724212308d05f43e8b1cdfbcde2b", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "d8649ee9-3320-4c00-86a4-c37a5ce3d779": {"doc_hash": "80c9a2b427f0dd2f252160024f4885d8225230c375688d4e712d8cc27e5c767d", "ref_doc_id": "069fd90a-ef1f-47f1-b80d-b81fec9951fa"}, "463ef6fd-52a1-4bc1-8563-5b0624d9c1d4": {"doc_hash": "a80570ceab04cff1f198e024e5bfacaed5cb29afb140252090b69365ab6337bf", "ref_doc_id": "a0849c01-d9f1-4fb3-b380-1baa6576b7a1"}, "5c2e36b3-6bbd-4f28-88da-b427633f0404": {"doc_hash": "6a884e6d94ca95f959900717ab14c5d53413e45362da7faf613b27541dd03cb4", "ref_doc_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e"}, "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444": {"doc_hash": "ba5625d029c2f059b188e0c8c58e58cce50df4124e111edd924446e734803b2d", "ref_doc_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e"}, "2f26af49-1cd8-45ca-9efe-2f65c776e289": {"doc_hash": "cfd38b8a3ccfc84c7794b1c7e4cf73076d625af99219c3cc24fc4031598ba743", "ref_doc_id": "234dff7a-a8e8-4f7c-9684-5f2c21b7732e"}, "620725a9-7f47-4be9-8b56-0e805e27fb60": {"doc_hash": "7fee452964fe680aaef577a36dc79e4c9380eb69875368b6ef5d4bf6ce978294", "ref_doc_id": "713e24e1-1374-496d-8092-46a267204fd0"}, "1cff24e4-a003-46a3-9834-00a8695f9027": {"doc_hash": "34bb931b6fa77303cd12337f3395689eb9ac6acc67ed7b513af0eb856db0a239", "ref_doc_id": "f3093538-a13a-442c-a1be-33f757d9c7c4"}, "42293786-271e-4381-88a1-e4eab57a42e0": {"doc_hash": "d073df7536f7b6994e75bec49e152773e12d3f21d05455659a2cac8284c27f27", "ref_doc_id": "f3093538-a13a-442c-a1be-33f757d9c7c4"}, "c29b67fd-47f5-4755-bc01-ebf63b5d60cb": {"doc_hash": "00c0b11ec3ec5e7343bebc2ed55019e588a4043d193c7bfea04dbcbf2a227f0c", "ref_doc_id": "f3093538-a13a-442c-a1be-33f757d9c7c4"}, "51f9dbe4-b365-4a81-8151-e2f0b5d145fc": {"doc_hash": "e80f16fec4f1fa11cc267cfba5bae64692637c027961254ffb4fdd75a10b853f", "ref_doc_id": "f3093538-a13a-442c-a1be-33f757d9c7c4"}, "c7a87305-1c03-4cbe-9d37-662e676df42b": {"doc_hash": "a5fd923e0b9c5ceb370d118e6c972a6670a664e20e6d7bee16190cdebfea7b1f", "ref_doc_id": "45cf4069-78c8-41e6-977a-0973d85f37d4"}, "991a4e59-e8ed-4f20-a613-131406a31e07": {"doc_hash": "0ac47517b31080876a459f21758543c9949ad44153b0869c3ab3e3fcb49748ce", "ref_doc_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6"}, "5d820226-35fb-41f2-bdd0-b4d328b0c4b9": {"doc_hash": "c43d675d0338fa9ccaaf942850a91e76556b22018cb86e8e446328b61f933ccc", "ref_doc_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6"}, "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877": {"doc_hash": "2af7acc6b530efb6549d1445ac4ec69562127a34407ba9b90043e228b78b8eef", "ref_doc_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6"}, "09893472-d7d3-45e4-ae97-ea9ff99893ed": {"doc_hash": "198175c348e20130c8977e6ac9e01ddc653f6ec07d19489de3500295abf4efbc", "ref_doc_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6"}, "2a61571f-c90e-46d3-a85a-03be966d723f": {"doc_hash": "c8f38dc82ced8ed944d6df140d4fc60d4aef498667316273871a3b8786557b83", "ref_doc_id": "af4848e7-c4e6-462d-9653-92f44ca84aa6"}, "f484c5a0-9183-4de6-bd44-bf0c775f220b": {"doc_hash": "70fbf29bda7f32177ad9d119288a8ec19f1066ef51dbc0685c19a424ba74986d", "ref_doc_id": "a8df1153-61d9-4086-a54c-90fb35aee650"}, "233542f9-e350-4022-a3da-3bf9402dc884": {"doc_hash": "789178013fa3277af2ee77d32c88682a69724a19239b51ff3d7a6123a80ec17b", "ref_doc_id": "a8df1153-61d9-4086-a54c-90fb35aee650"}, "2efeb5ca-96a8-493a-9681-e03f5da1cc3e": {"doc_hash": "a0396834813224834112400ad09fa2438406ed507d27fc77d8486edc2f439378", "ref_doc_id": "3b1d2ece-37c9-4a21-9b9d-4923baf01d43"}, "e8e963b5-a1fb-4612-b01a-fa55c58724d1": {"doc_hash": "3c23367a490a12f49a7557d9f412e06c102750d8536b9b3d0c17e6793bf61ba8", "ref_doc_id": "3b1d2ece-37c9-4a21-9b9d-4923baf01d43"}, "e9a4bbae-c69c-47fb-b20e-90e09456745a": {"doc_hash": "6116dbe347ac3597b47e80e49b2f8cde2572241b5207c07c7a0c6e25f5496e7f", "ref_doc_id": "53d4e1d4-c77a-4a8b-b9aa-b5d54e88c264"}, "853bb4da-dd21-4d07-b717-30becb8139f1": {"doc_hash": "c13dd612444f272c206b3023216f1852b358cb1ac7791c070f402b02a47b628b", "ref_doc_id": "53d4e1d4-c77a-4a8b-b9aa-b5d54e88c264"}, "897d6b41-1940-4a67-8cf8-d9cd8e35c771": {"doc_hash": "754ec21987c29d0391d50dc5bb989280e8d9145b4987f16ecc0d5ba49d921aa5", "ref_doc_id": "32bbbc25-898e-463a-a9cc-6761b80b482f"}, "c815a577-c922-4ea0-b458-b87fc28c2345": {"doc_hash": "512f14e9a8f6690132ed4f4871d059046c8ab30f787ffd30ed4028ea076e7cf3", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "a55b2fb3-6709-4de1-ad01-657f23414d97": {"doc_hash": "736e4ed27001b460518c413dccafc14fb8a41d351500930d1de16f37d0667d36", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "0cee8086-d8ae-4a14-be00-b01f7412cff3": {"doc_hash": "610d4d33adb93c39a9654afe5348bbd20b15f4963d5c61cfc2727e08e0e3545f", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3": {"doc_hash": "23744521a7dc3d4ba1e5709cf7bd79cd10e5095e8c2b579c1d4041e740264e33", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "bee17db7-d3b5-47b1-8bd0-d7137be7edf0": {"doc_hash": "71f3173e77cb88bab54313eb4260810004345686945ba39523e93accd9d4b6ad", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "c8c019b6-4e27-4a44-92dd-128a81c40aba": {"doc_hash": "c93c073906e4d5faebe1e597782405509a2fe0a5029828154472b2eee636c9ed", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "f783ba94-d8cc-4998-8a33-24e0d2023452": {"doc_hash": "f4bd914dc73185de28c885f399c12b78d2e49e1999ea870a2cbbf0f9a6c53ae9", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "7501f904-8e46-4ec6-88ab-0a11659a9612": {"doc_hash": "1ef3ffcd1ac6c4d2fa41ff1a034e695a0a0ffeb5fa7d34324545bb94ba60931f", "ref_doc_id": "90356f82-f373-469d-b5cf-20856364a6b5"}, "0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33": {"doc_hash": "5503c9fa8f4f8c9e78b3faba653de5f61ecc13bb9b9bd17133a61dd4c098952e", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "a7b8351f-558c-454c-a751-5d1b3dd1d644": {"doc_hash": "0416af2c9ab74b1df3ca6ab0607d967fb59d386eeac209ba7130023e06e200ce", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "741ae356-8ec9-424d-9ae8-43b6aef35994": {"doc_hash": "9501df4e5fb4e7a6f9d119fa34ae2d5f8b42ae1f7d5ea9e1ef4645f2edcec3ca", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "06ee30e1-d439-4efe-a16d-c86c9ac337f8": {"doc_hash": "eba767ab8322376dd083c87e4bb5de055aa3d3200fbda55a79b9713cd7123471", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "15361238-30a2-4022-8063-38fbc1c9c87b": {"doc_hash": "b21c02f27370bf6ba7d4ae87142d3da1ce5453c36ffa140f7fa64de7565eebf6", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "faad9df0-f4b2-4868-bd75-baf6cf4887ee": {"doc_hash": "7fabb35417f06cf0f655f7b4686565fc5b635224ddb14c726e15f35013d4148a", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "554c6189-2850-4e44-ad84-62cb17888a5f": {"doc_hash": "6d490ec101fafb0850133e2fd244e9a09aa876385aca056af7cbf6f2afa95463", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "4108abc1-9c86-44d1-a5c4-8ba7a975a421": {"doc_hash": "236af5d7747c173cbfa0e646a881ba1b011d2043b59c8435589883fba6e96fac", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "31f246aa-6b36-4d79-90bc-a2ec63eba0b8": {"doc_hash": "89a9e93b0be11ba71b5f1dd6af4b3aec4224095ce00bebd708368fb295b894e6", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "47c527b8-43af-451e-b533-6025a5a94ee9": {"doc_hash": "f8c34d17305cd2b8f57b036cbb89766240caef66757058fdef058f2c81797f0d", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "096e3de6-231e-44ff-aa56-12e0d56fb2be": {"doc_hash": "2c37ba936d44b354b1e041b67e68b200fe206f9bc4b29cf7dc966a20f7b36a33", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "1c2464b8-5f35-4ecc-9a32-26023c21c13b": {"doc_hash": "db6da65d2a7376704dc2ecd2841813ddcb7f8c06ce7984d807ab2e04129ff81a", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b": {"doc_hash": "e92f616f1f1628b39fd0ac7e643cda92ab7cdeb4e444589f895ab56733937e9f", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "aa33bccb-7133-4233-8e9a-ec32d6a92ece": {"doc_hash": "8ec86d156ddd811b9940c52c7e59558bd9816353ff212c7f99db30ec681879f5", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "a2725962-e0a5-4d0b-a448-22e8dbd8c38e": {"doc_hash": "888bdfb39eaece7229d23579a4bb2e10d2e790834822c9f1be84c0eed59442cc", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "d1f418b5-3ddb-43ca-a856-50c12484f786": {"doc_hash": "2735466ad5d540de6fead684e5826bb510fbae13d7c26573388f9a7b38b319ce", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "e7a211ee-fe01-48c4-8e4b-36c43305c716": {"doc_hash": "cbc85d25551da7c37c499138b7d8dbae54d3bfb274bf432c9a4e8d4f4c00c20d", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8": {"doc_hash": "9ca3b074fdfdcb64330ee3fb0a2bb52149d09f0929c50d903e7babc9abaa2520", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "b69a61cf-d15a-4303-b547-4285c7ce4d92": {"doc_hash": "e8c446eee111dc5a359aa610dd47a2fbf9b2d07d3c624cdfeba1a522ec0d900e", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "217089ee-4d2f-4aaa-869b-903f9e838382": {"doc_hash": "7481e5baa7e6dbd45c9e3592818c9b5748bf7225a22cdc83d2df9d522e9a6a24", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03": {"doc_hash": "ad886a2f18a1fcb0553b19feba18be35a2c82b76fc6212f33f0d4ede6a4eaebc", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "a79b6b4a-b8e1-4c10-b652-77d434623ffb": {"doc_hash": "69376916062b78ecaa5019dc50c84991e8c57ad57e6bcb29b825fbc98f339149", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "a3e2ae5f-196a-4e8f-aba6-2b34d2513625": {"doc_hash": "33d711faea4a820a3f86c999883c5624a582ccf7b4360f9f97d2da85ebab5d43", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0": {"doc_hash": "3ae12d35cb34e3ee828c384401e80d972e7325e0cc77c0823f9d4524ea77fd14", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "5c87766f-ea6c-4f26-a84c-c6c825e1be3f": {"doc_hash": "206edfcf2f6e565cdfe18af73ebbf7966663509886192800dd6c0295a745900b", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8": {"doc_hash": "596a1d070e4875f9479f0e42f49d21c200a555483f4fe10dec75254ed17a4262", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "5c701598-9bfa-4477-a0e8-c5fd4312b091": {"doc_hash": "7ad787055e67b195fd8f6ac621e8dda0e4baa880859f8a9078bb96caf3d6d4e5", "ref_doc_id": "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8"}, "d983686f-ceac-4f73-b65f-967f45efa739": {"doc_hash": "0f8e7828c67c7c261927cd6d6b136a733f3c8cc0f6e5a7a8c92f745d8b161bcb", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801": {"doc_hash": "d56e61c0a59ab16de99dfd133ec009c1442bd5a6521a49d6fb459a27265e4be0", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "5dad915d-60e4-40f6-bd62-46be6b5bbbc2": {"doc_hash": "ecd962e2b339c067c9fda54552bfd7378ee809b9f28f7450de412cbf59635759", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "0c591a12-3228-46d0-a3df-deebf0ca250c": {"doc_hash": "417bed74c186f4dcdc2b25b460a6b4890235e3bda4e7711189e5c1f63f958d7a", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "a2b870f8-2e84-4dc6-bc88-60fba1cdab90": {"doc_hash": "f3c8969dffffdd25b6804a4ede7dd49f622755c19a9fbb0e6f640d7e45a09c62", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef": {"doc_hash": "1beb5cc688ebdf2878b0e4475549be8bd3fc856090e43675de8bf56edb556586", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2": {"doc_hash": "1a465ef59859735b29b4d836217e5111f5e91de22fde09014f1f9715be488aab", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "f1e1e6c7-caca-4a49-8e71-ba108a0a4666": {"doc_hash": "322363593238bcf51f7ca6dd71312ed763a64a358ac8df947289d1e93ec9a14d", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "eb273229-51cd-4ed0-8402-e4ca99af5659": {"doc_hash": "44aeaf7a992e132f101328215bda72251a734a98710457f431a5ac4245340b55", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "67ffbe03-8c49-4c3b-a433-47dd989d9f97": {"doc_hash": "29dfe696d3c1f8104386fc07b148214b28d1c1a53cb66511f1e9719f41a96df3", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "43d09fe2-749c-4118-afb9-5a6ec11afc5a": {"doc_hash": "738ac991236adbb6786ee634982d1e0698ce492c3deb994327ae3a91065fa893", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "a6e64b94-7721-4ae6-af8b-22a7ff30243a": {"doc_hash": "45e09c0738ea0630a112da23762d094efe3bb4edcbbdba4b9424d581aeea2e74", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "efe8ceae-8693-4c3a-adc3-1bc2bf417d78": {"doc_hash": "09c2af7b93186b35fc0e86a591a232f0a8d5f651a866fc99de715776057b5b43", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "c7891970-599d-40a6-bfd5-1006ce03b4a8": {"doc_hash": "505e76fe6e09a3b850397dbcf63eae5fe01425c76983ac62357cada47982b1d3", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "b39c5648-72bf-401f-9f88-c421860a6ebe": {"doc_hash": "8a48a3102e0d7460dc39c972eab0f7adf0cde7378846de98efb839069a19d187", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "ffba1e90-2d40-4dbb-9810-a5a52c599848": {"doc_hash": "581deaed45e333c07b8ab82614a7e5f16a78d613879cdca3a8e1900d3e6fd2ea", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}, "bb468a74-a11a-4bc1-acac-7c16a44523c1": {"doc_hash": "f60f73af861487a822bb59463be320eac70bd6ccab8a97ed22f046a47868375e", "ref_doc_id": "f19bb5f4-e297-47b6-a6c3-62949b53b115"}}, "docstore/ref_doc_info": {"6f1a3c5a-1185-4bb5-9d2f-56f6e3a85d9e": {"node_ids": ["15b1e7c0-a55a-4ee8-a86a-b667818374bb", "54cda69d-0b0f-45ee-923d-47d2adac06c5", "4ebd334f-e3ad-4f56-93ed-d98766d8642f", "44bfbd15-d9fd-49fe-930b-71feffa4192f", "abff7cdc-e01b-4a0f-b19d-cfbf22ff0c82", "d45a0f7a-dfba-41e5-957b-7d56c6b6f34b", "3968f0fa-8aea-4f3e-80e4-5b65b68ca2c8", "e6b2d323-9ac3-45a9-ab5a-f66b67fe6dbd", "896cd2e8-5806-40fd-8f0a-ea2628e6a024", "bc9f552d-b9c2-4f15-9ef3-a1f0f5cc5825", "6557afe0-45c2-40f3-b090-ebe21613a7f0"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.33 for the first quarter of fiscal 2023 compared to\n$2.13 in the prior year first quarter.  Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described\nbelow, increased 5.0 percent to $2.71 in the fiscal first quarter from $2.58 in the prior year first quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2023 Fir st Quar ter Results\n2/1/2023\nRevenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year \n First Quarter GAAP Diluted EPS of $2.33 and Adjusted Diluted EPS of $2.71 \n Adjusted Diluted EPS Guidance Range Raised to $11.50 to $11.75 for Fiscal 2023\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2023\nfirst quarter ended December 31, 2022, revenue increased 5.4 percent year-over-year to $62.8 billion. ", "page_label": "1", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f82c1cbe-38c9-45b5-9c13-9b82dcdd786a": {"node_ids": ["c7987cd0-7555-4873-9819-61f60c9df33c", "2c99447e-71b3-45a1-9554-0d2484aa9151", "31de26dc-cb4a-4883-b3a2-e16b20fdfb68", "e3157dac-10c8-4fae-aee2-d48e1e5f305a", "767585d5-7f82-4157-b1b2-708bb2abe359", "2a451e02-04ec-4953-b340-52c537c67c07", "fde71149-4758-4ef5-a17e-473523a42c48", "497fea0e-ce4a-4e6e-bd7a-20d0a52ebc11", "197ac244-55f8-4e3a-a0d0-b8d9653882b0", "08e411bd-c1b8-42af-8cdf-fcd12868f0fd", "15bfd802-87f2-467e-8b79-664897e53bbe", "32d63ee3-d045-493a-967d-7eaef97aac9b", "403b7d97-859c-4e07-8ed0-473859727237", "cfbcedca-4a9d-4d76-b976-b7c2c89d412d", "5b4ca3ab-f6d5-4bff-9728-836b33105f44", "1057aad3-cf94-4132-96f7-2b7f3a71dfcf", "34fbe4fb-7166-4810-9b53-a414d785e719", "939fcbbe-9790-411a-9a9d-c563becca4a4", "11514d0e-faa1-4480-972b-8cf0cbee0627", "665794a7-3fe6-4c9d-a59d-6b18b85488e7", "4f25294a-d0a5-4ab8-b6e5-be88cf6bf55c", "a416c874-637a-48ba-9b92-9986d737a006", "dd1355bd-210f-4697-8a22-c1c6a91d5080"], "metadata": {"window": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d following the tables.\n First Quar ter GAAP R esults\nRevenue:  In the first quarter of fiscal 2023, revenue was $62.8 billion, up 5.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 6.1 percent increase in revenue within U.S. ", "original_text": "Dilut ed Earnings P er Shar e $2.33 $2.71\nDilut ed Shar es Outstanding 206.3M 206.3M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7f70d5c2-1cc5-40d5-8e65-a4bbe713ccc7": {"node_ids": ["fe5490f3-fe33-448a-bbbe-58972cff51a0", "4d7fd800-40a4-4dff-8b8a-cb15debe0045", "56a079b3-002e-4f90-aca4-bf5cfe721d08", "fce4c8c4-e877-495e-98a8-535098a314b5", "70b5da4a-8e39-4bd3-a8fc-984101b0b5de", "afe396e1-7f48-43be-83c2-9358273888d0", "a991c8ad-d945-46b0-b02d-b0d84e37e676", "c274179a-5980-4e78-931c-637a694a0991", "aa0d6695-fc1f-46de-9da1-81e3d5dda1b3", "5ecec636-a153-4055-a531-c434d1d9babf", "b5060665-b5e1-4ccc-a22d-0ab74b811c83", "2737015e-5317-48ac-85d1-7d625236503c", "e75a9f66-3540-4a3e-b1dc-f4447912c6d9", "13e21864-44de-45cf-8a58-ee90d747b90a", "8c8443f2-d873-4e0f-9c93-a78e8d953a84", "9dbe802e-d65f-4f23-a031-6e155663469c", "757a4747-4c4c-4185-9d13-88424a46b17d", "c8478656-1f44-4cd0-9e72-89bf3bfc505d", "a724bed0-253a-471b-84fa-4116e09c3c21", "0de87473-b6b1-4fff-947f-b22f5a626084", "8a4cda22-09ea-4afc-8111-58c1f73c128b", "ff2bdccf-7052-419f-8f28-448d12f9b071", "bb04fb34-3d5b-483b-b74a-cf239a7b1183", "605f6271-96d7-46fa-b2fd-62f66077e314", "95e6671c-7b31-4fb4-988c-2d2c0049d613", "5763c603-49dc-4fa9-9c01-988b62fc461f", "3959970a-2948-4214-9ddb-880e8784849a"], "metadata": {"window": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business.  On a\nconstant currency basis, revenue was up 7.5 percent, reflecting 17.7 percent constant currency growth in International\nHealthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the first quarter of fiscal 2023 was $2.1 billion, a 5.4 percent increase compared\nto the same period in the previous fiscal year primarily due to an increase in gross profit in U.S.  Healthcare Solutions, driven\nby increased sales. ", "original_text": "primarily resulting from unfavorable foreign currency exchange rates in the current year quarter in comparison to the prior\nyear quarter, offset in part by an increase in sales in our less-than-wholly-owned Brazil full-line distribution business. ", "page_label": "3", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a9f502a5-4335-49bd-8223-0791e4b172c3": {"node_ids": ["25e0ea99-2c72-4f42-bb25-a759f249b9ae", "3e2dcd19-e214-4fd8-be65-a86d238f33a1", "51f9f617-144b-4da9-96ad-55f82d55747d", "bb9623f4-cf1b-41ab-8f5f-c4c952d98808", "eca8983b-f1bd-4232-8306-6ef8d05c1e02", "345eacb6-1636-40f1-9fcf-a96e24fa245f", "eb2daec6-e492-4bbe-9973-da6f663cfe74", "21028618-b0b3-4dd5-b9eb-c3e34ef45557", "291e11dc-f5a5-406a-a269-635a457c2305", "db832058-5154-4ccf-9031-5c822af6071d", "20e90243-8f48-4f68-855e-4ba29f1f1baa", "48eb52d4-fd32-47d3-8875-f9e8c471d698", "21172005-daa3-4378-826c-8ec471f82e70", "7ab02006-a659-453d-853a-0cb0e964161e", "4bb765d5-2968-499a-b58a-891d7655b3e6", "53bb4c6b-f7d4-44ac-bf55-b1ecf48a0215", "0d5e55b6-56ad-452e-864c-b90064c7845d", "dea15763-144f-4bf3-a06c-214a7be8e21d", "f9102cdb-223c-4de5-b441-14db59edbb01", "b77fa293-2edf-42a7-b64a-b43e887075cb"], "metadata": {"window": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter.  Segment operating income in the first quarter of fiscal 2023 was $161.3 million, a decrease of 10.4\npercent.  The period over period declines were due to unfavorable foreign currency exchange rates in the current year quarter in\ncomparison to the prior year quarter and the June 2022 divestiture of our Brazil specialty business.  On a constant currency basis,\nInternational Healthcare Solutions revenue and operating income increased by 17.7 percent and 10.8 percent, respectively.\n", "original_text": "Revenue in International Healthcare Solutions was $6.6 billion in the first quarter of fiscal 2023, a decrease of 0.6 percent from the\nprevious fiscal year\u2019s first quarter. ", "page_label": "4", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "af3278b2-63d4-4163-ae9b-c159922c35aa": {"node_ids": ["699349b9-f0fc-4d12-82d0-c332caefcc25", "fdd0e06c-714e-45b2-b834-acf54caaccae", "0421e8a4-2589-4bad-8fb5-68f7501bb891", "494bbb25-2e97-4aa8-8c60-a6712e37df85", "5e048306-925b-4ae9-8ce2-2827e4cc4c81", "5a5f89d1-9384-4246-84fd-14944aaa72fe", "4d910207-a785-4cab-a84e-4ace90d34875", "b3e42cbd-a35e-46ef-8c19-33ce91f37fe5", "ccdca928-32b5-4d84-a630-c4e2d3989e9c", "b4f77887-d0e0-43a9-bc4d-60b42a7acaae", "f146e8cc-7eb2-4315-a6ca-f905310b9f2c", "b747e0ca-b6f0-4c90-ae98-a0daa64ce51a", "6f159e87-6b94-4026-8502-8926a87a351f", "e6a94759-6f4f-4d24-b44a-9ff3da919f16", "bbfaca59-780a-4316-982a-db79b85b31f7", "7926e76b-afda-4f16-8805-b5a72d4cf770", "2e78a047-26a7-45a1-8adb-c671cca3a18a", "6283bb1d-fda4-4239-b923-553a3225d5a5", "6b08f357-75d3-4702-8826-f8bc86c03386", "9469b69f-9994-428c-96bf-48afc44fbdf1", "e77e9336-dd87-4997-a87c-a7669b9ad69c", "de05f0a5-a277-4ea1-9e1c-ec1137a4a0d8", "2d3ffbc3-5ed4-4d35-8367-af13dfab9320", "f8754a0a-bb64-40a4-9a3f-a04ffa4698f0", "e5af2fc8-b068-4e50-b1fc-53b902634dcf", "bf4fce91-76e0-4395-b5aa-a64c95c35a52", "0edf3dc4-e6a7-47db-8c6b-40c7dda589b5"], "metadata": {"window": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n All other previously communicated aspects of the Company\u2019s fiscal year 2023 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company\u2019s Board of Directors declared a quarterly cash dividend of $0.485 per common share, payable February 27, 2023, to\nstockholders of record at the close of business on February 10, 2023.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "Weighted average diluted shares to be approximately 206 million shares for the fiscal year, lowered from the previous range\nof approximately 207 to 209 million shares;\nFor additional details regarding updated guidance expectations on a constant currency, ex-COVID and ex-merger and\ndivestiture basis please refer to our slide presentation for investors.\n", "page_label": "5", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "069fd90a-ef1f-47f1-b80d-b81fec9951fa": {"node_ids": ["eef8b813-89ed-4245-8570-cfc722b06c59", "24829ef8-6bc6-4b34-8466-cdd0a2f17cad", "74fbd71d-0b62-47b9-aa34-7d77d1dae430", "3e3b232b-053a-446b-95ea-a5f9af1fffd2", "5a622475-2df3-4c04-8bdf-508c272803fe", "e6ec5399-f0b8-492c-bb14-cdad36aafcc7", "19fba8d1-c28e-4332-991f-b426328b270a", "a0b92e8d-0d16-43b2-9677-6484973a13b8", "d8649ee9-3320-4c00-86a4-c37a5ce3d779"], "metadata": {"window": "similar expressions are intended to identify such forward-looking statements.  These statements are based on management\u2019s current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic\n(including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability\nto achieve and maintain profitability in the future; our ability to respond to general economic conditions, including elevated levels of\ninflation; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the Alliance\nHealthcare and PharmaLex businesses into the Company being more difficult, time consuming or costly than expected; the\nCompany\u2019s, Alliance Healthcare\u2019s or PharmaLex\u2019s failure to achieve expected or targeted future financial and operating performance\nand results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the\nCompany, Alliance Healthcare and PharmaLex, and the fact that the acquisition and related strategic transactions may make it more\ndifficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses,\nincluding the acquisition of the Alliance Healthcare and PharmaLex businesses and related strategic transactions, that do not\nperform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "original_text": "similar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a0849c01-d9f1-4fb3-b380-1baa6576b7a1": {"node_ids": ["463ef6fd-52a1-4bc1-8563-5b0624d9c1d4"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nDecember 31,\n2022 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nDecember 31,\n2021 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$62,846,832 \u00a0\u00a0\u00a0 \u00a0$59,628,810 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a060,700,879 \u00a0\u00a0\u00a0 \u00a0\u00a057,568,451 \u00a0\u00a0\u00a0 \u00a05.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,145,953 \u00a0\u00a03.41 %\u00a0\u00a02,060,359 \u00a0\u00a03.46 %\u00a04.2 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,290,928 \u00a0\u00a02.05 %\u00a0\u00a01,170,110 \u00a0\u00a01.96 %\u00a010.3 %\nDepreciation and amortization \u00a0\u00a0171,940 \u00a0\u00a00.27 %\u00a0\u00a0175,929 \u00a0\u00a00.30 %\u00a0(2.3 )%\nLitigation and opioid-related expenses \u00a0\u00a012,706 \u00a0\u00a0\u00a0 \u00a0\u00a032,635 \u00a0\u00a0\u00a0 \u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a037,236 \u00a0\u00a0\u00a0 \u00a0\u00a032,334 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,512,810 \u00a0\u00a02.41 %\u00a0\u00a01,415,954 \u00a0\u00a02.37 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0633,143 \u00a0\u00a01.01 %\u00a0\u00a0644,405 \u00a0\u00a01.08 %\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net \u00a0\u00a0(6,328 )\u00a0\u00a0 \u00a0\u00a0(5,172 )\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a046,016 \u00a0\u00a0\u00a0 \u00a0\u00a053,372 \u00a0\u00a0\u00a0 \u00a0(13.8 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0593,455 \u00a0\u00a00.94 %\u00a0\u00a0596,205 \u00a0\u00a01.00 %\u00a0(0.5 )%\n7", "page_label": "7", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "234dff7a-a8e8-4f7c-9684-5f2c21b7732e": {"node_ids": ["5c2e36b3-6bbd-4f28-88da-b427633f0404", "0b8d77f6-4fb2-4bf3-a533-15fbb6fa1444", "2f26af49-1cd8-45ca-9efe-2f65c776e289"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n Includes $44.7 million LIFO credit in the three months ended December 31, 2021.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n8", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0117,285 \u00a0\u00a0\u00a0 \u00a0\u00a0146,789 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0476,170 \u00a0\u00a00.76 %\u00a0\u00a0449,416 \u00a0\u00a00.75 %\u00a06.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet loss (income) attributable to noncontrolling\ninterests \u00a0\u00a03,575 \u00a0\u00a0\u00a0 \u00a0\u00a0(311 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen\nCorporation \u00a0$479,745 \u00a0\u00a00.76 %\u00a0$449,105 \u00a0\u00a00.75 %\u00a06.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.35 \u00a0\u00a0\u00a0 \u00a0$2.15 \u00a0\u00a0\u00a0 \u00a09.3 %\nDiluted \u00a0$2.33 \u00a0\u00a0\u00a0 \u00a0$2.13 \u00a0\u00a0\u00a0 \u00a09.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0204,032 \u00a0\u00a0\u00a0 \u00a0\u00a0208,555 \u00a0\u00a0\u00a0 \u00a0(2.2 )%\nDiluted \u00a0\u00a0206,327 \u00a0\u00a0\u00a0 \u00a0\u00a0211,168 \u00a0\u00a0\u00a0 \u00a0(2.3 )%\n________________________________________\n\u00a0\n1Includes $49.9 million gain from antitrust litigation settlements and $25.1 million LIFO expense in the three months ended\nDecember 31, 2022.\n", "page_label": "8", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "713e24e1-1374-496d-8092-46a267204fd0": {"node_ids": ["620725a9-7f47-4be9-8b56-0e805e27fb60"], "metadata": {"window": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "original_text": "\u00a0 \u00a0Three Months Ended December 31, 2022 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,145,953 \u00a0\u00a0$1,512,810 \u00a0\u00a0$633,143 \u00a0\u00a0$593,455 \u00a0\u00a0$117,285 \u00a0\u00a0$3,575 \u00a0\u00a0$479,745 \u00a0\u00a0$2.33 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0\u00a0(49,899 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(49,899 )\u00a0\u00a0(49,899 )\u00a0\u00a0(11,659 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(38,240 )\u00a0\u00a0(0.19 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTurkey highly\ninflationary\nimpact \u00a0\u00a03,584 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,584 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,986 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a0\u00a025,050 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a025,050 \u00a0\u00a0\u00a05,853 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a019,197 \u00a0\u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(71,878 )\u00a0\u00a071,878 \u00a0\u00a0\u00a071,878 \u00a0\u00a0\u00a016,795 \u00a0\u00a0\u00a0(1,158 )\u00a0\u00a053,925 \u00a0\u00a0\u00a00.26 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(12,706 )\u00a0\u00a012,706 \u00a0\u00a0\u00a012,706 \u00a0\u00a0\u00a02,969 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a09,737 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(37,236 )\u00a0\u00a037,236 \u00a0\u00a0\u00a037,236 \u00a0\u00a0\u00a08,700 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a028,536 \u00a0\u00a0\u00a00.14 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nRecovery of\nnon-customer\nnote receivable \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,148 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,457 )\u00a0\u00a0(8,364 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,907 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n9", "page_label": "9", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f3093538-a13a-442c-a1be-33f757d9c7c4": {"node_ids": ["1cff24e4-a003-46a3-9834-00a8695f9027", "42293786-271e-4381-88a1-e4eab57a42e0", "c29b67fd-47f5-4755-bc01-ebf63b5d60cb", "51f9dbe4-b365-4a81-8151-e2f0b5d145fc"], "metadata": {"window": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs.  prior year \u00a0\u00a05.4 %\u00a0\u00a09.8 %\u00a0\u00a0(2.1)\n%\u00a0\u00a0(1.0)\n%\u00a0\u00a0(11.2)\n%\u00a0\u00a0 \u00a0\u00a02.6 %\u00a0\u00a05.0 %\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.41 %\u00a03.38 %\nOperating\nexpenses \u00a02.41 %\u00a02.21 %\nOperating\nincome \u00a01.01 %\u00a01.17 %\n________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended December 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income \n Tax\nExpense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,060,359 \u00a0\u00a0$1,415,954 \u00a0\u00a0$644,405 \u00a0\u00a0$596,205 \u00a0\u00a0$146,789 \u00a0\u00a0$(311 )\u00a0$449,105 \u00a0\u00a0$2.13 \u00a0\u00a0\n10", "original_text": "Adjusted Non-\nGAAP \u00a0$2,124,688 \u00a0\u00a0$1,390,990 \u00a0\u00a0$733,698 \u00a0\u00a0$688,807 \u00a0\u00a0$131,579 \u00a0\u00a0$2,417 \u00a0\u00a0$559,645 \u00a0\u00a0$2.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP % change\nvs. ", "page_label": "10", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "45cf4069-78c8-41e6-977a-0973d85f37d4": {"node_ids": ["c7a87305-1c03-4cbe-9d37-662e676df42b"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(44,679 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(44,679 )\u00a0\u00a0(44,679 )\u00a0\u00a0(10,245 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(34,434 )\u00a0\u00a0(0.16 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(79,506 )\u00a0\u00a079,506 \u00a0\u00a0\u00a079,506 \u00a0\u00a0\u00a018,230 \u00a0\u00a0\u00a0(1,790 )\u00a0\u00a059,486 \u00a0\u00a0\u00a00.28 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLitigation and\nopioid-related\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,635 )\u00a0\u00a032,635 \u00a0\u00a0\u00a032,635 \u00a0\u00a0\u00a05,919 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a026,716 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition,\nintegration, and\nrestructuring\nexpenses \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(32,334 )\u00a0\u00a032,334 \u00a0\u00a0\u00a032,334 \u00a0\u00a0\u00a07,414 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,920 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax expense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(11,079 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a011,079 \u00a0\u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(5,307 )\u00a0\u00a0(8,875 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a03,568 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,015,680 \u00a0\u00a0$1,266,533 \u00a0\u00a0$749,147 \u00a0\u00a0$695,640 \u00a0\u00a0$148,153 \u00a0\u00a0$(2,101 )\u00a0$545,386 \u00a0\u00a0$2.58 \u00a0\u00a0\n\u00a0\nPercentages o f\nRevenue: GAAPAdjust ed\nNon-GAAP\nGross profit \u00a03.46 %\u00a03.38 %\nOperating\nexpenses \u00a02.37 %\u00a02.12 %\nOperating income \u00a01.08 %\u00a01.26 %\n11", "page_label": "11", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "af4848e7-c4e6-462d-9653-92f44ca84aa6": {"node_ids": ["991a4e59-e8ed-4f20-a613-131406a31e07", "5d820226-35fb-41f2-bdd0-b4d328b0c4b9", "e387a52c-1fd7-4d31-a7dd-c8c68f1fb877", "09893472-d7d3-45e4-ae97-ea9ff99893ed", "2a61571f-c90e-46d3-a85a-03be966d723f"], "metadata": {"window": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0 \u00a0Three Months Ended December 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions $56,236,579 \u00a0$52,979,647 \u00a06.1 %\nInternational Healthcare Solutions \u00a06,611,278 \u00a0\u00a06,649,782 \u00a0(0.6 )%\nIntersegment eliminations \u00a0(1,025 )\u00a0(619 )\n\u00a0\nRevenue $62,846,832 \u00a0$59,628,810 \u00a05.4 %\n\u00a0\nThree Months Ended December 31,\nOperating income \u00a0\u00a02022 \u00a0\u00a0\u00a02021 \u00a0\u00a0% Change\nU.S. ", "original_text": "________________________________________\n\u00a0\n1Tax expense relating to 2020 Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets, the\nlatter of which is recorded within Other Income, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a8df1153-61d9-4086-a54c-90fb35aee650": {"node_ids": ["f484c5a0-9183-4de6-bd44-bf0c775f220b", "233542f9-e350-4022-a3da-3bf9402dc884"], "metadata": {"window": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.46 %\u00a0\u00a02.41 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.45 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.02 %\u00a0\u00a01.07 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.17 %\u00a0\u00a011.08 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.73 %\u00a0\u00a08.38 %\u00a0\u00a0\nOperating income \u00a0\u00a02.44 %\u00a0\u00a02.71 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.41 %\u00a0\u00a03.46 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.41 %\u00a0\u00a02.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.01 %\u00a0\u00a01.08 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.38 %\u00a0\u00a03.38 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.21 %\u00a0\u00a02.12 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.17 %\u00a0\u00a01.26 %\u00a0\u00a0\n13", "original_text": "Acquisition-related intangibles amortization \u00a0\u00a0(71,878 )\u00a0\u00a0(79,506 )\u00a0\u00a0\nLitigation and opioid-related expenses \u00a0\u00a0(12,706 )\u00a0\u00a0(32,635 )\u00a0\u00a0\nAcquisition, integration, and restructuring expenses \u00a0\u00a0(37,236 )\u00a0\u00a0(32,334 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a0\nOperating income \u00a0$633,143 \u00a0\u00a0$644,405 \u00a0\u00a0(1.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "13", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3b1d2ece-37c9-4a21-9b9d-4923baf01d43": {"node_ids": ["2efeb5ca-96a8-493a-9681-e03f5da1cc3e", "e8e963b5-a1fb-4612-b01a-fa55c58724d1"], "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 December 31, \u00a0September 30,\n\u00a0 2022 \u00a02022\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $1,692,205 \u00a0$3,388,189\nAccounts receivable, net \u00a018,627,397 \u00a0\u00a018,452,675\nInventories \u00a016,779,873 \u00a0\u00a015,556,394\nRight to recover assets \u00a01,529,346 \u00a0\u00a01,532,061\nPrepaid expenses and other 1 \u00a02,079,304 \u00a0\u00a0660,439\nTotal current assets \u00a040,708,125 \u00a0\u00a039,589,758\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,139,782 \u00a0\u00a02,135,003\nGoodwill and other intangible assets \u00a013,027,027 \u00a0\u00a012,836,623\nDeferred income taxes \u00a0230,437 \u00a0\u00a0237,571\nOther long-term assets \u00a01,801,522 \u00a0\u00a01,761,661\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,906,893 \u00a0$56,560,616\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n14", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \u201cSupplemental Information\nRegarding Non-GAAP Financial Measures\u201d of this release.\n", "page_label": "14", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "53d4e1d4-c77a-4a8b-b9aa-b5d54e88c264": {"node_ids": ["e9a4bbae-c69c-47fb-b20e-90e09456745a", "853bb4da-dd21-4d07-b717-30becb8139f1"], "metadata": {"window": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Three Months Ended\nDecember 31,\n\u00a0 \u00a02022 \u00a0\u00a0\u00a02021 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $476,170 \u00a0\u00a0$449,416 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0242,947 \u00a0\u00a0\u00a0221,652 \u00a0\n15", "original_text": "Current liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $41,757,949 \u00a0$40,192,890\nOther current liabilities \u00a02,014,399 \u00a0\u00a02,214,592\nShort-term debt \u00a0988,275 \u00a0\u00a01,070,473\nTotal current liabilities \u00a044,760,623 \u00a0\u00a043,477,955\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,656,029 \u00a0\u00a04,632,360\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0329,129 \u00a0\u00a0320,274\nDeferred income taxes \u00a01,633,249 \u00a0\u00a01,620,413\nOther long-term liabilities \u00a0991,609 \u00a0\u00a0976,583\nAccrued litigation liability \u00a05,462,695 \u00a0\u00a05,461,758\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a073,559 \u00a0\u00a071,273\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders\u2019 equity $57,906,893 \u00a0$56,560,616\n1 At December 31, 2022, includes $1,438.1 million prefunding of the PharmaLex acquisition that was completed on January 1, 2023.\n", "page_label": "15", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "32bbbc25-898e-463a-a9cc-6761b80b482f": {"node_ids": ["897d6b41-1940-4a67-8cf8-d9cd8e35c771"], "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(59,872 )\u00a0\u00a0716,380 \u00a0\nInventories \u00a0(1,178,035 )\u00a0\u00a0(989,993 )\nAccounts payable \u00a01,381,079 \u00a0\u00a0\u00a0824,056 \u00a0\nOther, net \u00a0(152,209 )\u00a0\u00a0(358,100 )\nNet cash provided by operating activities \u00a0710,080 \u00a0\u00a0\u00a0863,411 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(75,727 )\u00a0\u00a0(79,691 )\nCost of acquired companies, net of cash acquired \u00a0\u2014 \u00a0\u00a0\u00a0(62,641 )\nPrefunded business acquisition \u00a0(1,438,124 )\u00a0\u00a0\u2014 \u00a0\nOther, net \u00a02,693 \u00a0\u00a0\u00a0(788 )\nNet cash used in investing activities \u00a0(1,511,158 )\u00a0\u00a0(143,120 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt repayments \u00a0(10,518 )\u00a0\u00a0(6,486 )\nPurchases of common stock 1 \u00a0(807,214 )\u00a0\u00a0\u2014 \u00a0\nExercises of stock options \u00a021,863 \u00a0\u00a0\u00a038,937 \u00a0\nCash dividends on common stock \u00a0(99,713 )\u00a0\u00a0(100,541 )\nEmployee tax withholdings related to restricted share vesting \u00a0(65,217 )\u00a0\u00a0(34,554 )\nOther, net \u00a0(3,145 )\u00a0\u00a0(3,779 )\nNet cash used in financing activities \u00a0(963,944 )\u00a0\u00a0(106,423 )\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a084,140 \u00a0\u00a0\u00a0(2,654 )\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale \u00a0(1,680,882 )\u00a0\u00a0611,214 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "90356f82-f373-469d-b5cf-20856364a6b5": {"node_ids": ["c815a577-c922-4ea0-b458-b87fc28c2345", "a55b2fb3-6709-4de1-ad01-657f23414d97", "0cee8086-d8ae-4a14-be00-b01f7412cff3", "dd6b3fe0-7769-4224-ab3f-86ce5b484ef3", "bee17db7-d3b5-47b1-8bd0-d7137be7edf0", "c8c019b6-4e27-4a44-92dd-128a81c40aba", "f783ba94-d8cc-4998-8a33-24e0d2023452", "7501f904-8e46-4ec6-88ab-0a11659a9612"], "metadata": {"window": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n 2The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0December 31, \n2022 \u00a0September 30, \n2022 \u00a0December 31, \n2021 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$1,692,205 \u00a0$3,388,189 \u00a0$3,168,881 \u00a0$2,547,142\nRestricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0159,599 \u00a0\u00a0144,980 \u00a0\u00a0453,485 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,853 \u00a0\u00a060,370 \u00a0\u00a060,014 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$1,912,657 \u00a0$3,593,539 \u00a0$3,682,380 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "Plus: Decrease in cash classified within assets held for sale \u00a0\u2014 \u00a0\u00a0\u00a01,038 \u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash \u00a0(1,680,882 )\u00a0\u00a0612,252 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 2 \u00a03,593,539 \u00a0\u00a0\u00a03,070,128 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 2 $1,912,657 \u00a0\u00a0$3,682,380 \u00a0\n________________________________________\n\u00a0\n1Includes $28.4 million of purchases in September 2022 that cash settled in October 2022.\n\u00a0\n", "page_label": "17", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cb5c55cd-4fc8-42ad-94b3-fc8ae1ecfda8": {"node_ids": ["0b3138ca-bf7a-4fd5-9fb6-9dd40f06af33", "a7b8351f-558c-454c-a751-5d1b3dd1d644", "741ae356-8ec9-424d-9ae8-43b6aef35994", "06ee30e1-d439-4efe-a16d-c86c9ac337f8", "15361238-30a2-4022-8063-38fbc1c9c87b", "faad9df0-f4b2-4868-bd75-baf6cf4887ee", "554c6189-2850-4e44-ad84-62cb17888a5f", "4108abc1-9c86-44d1-a5c4-8ba7a975a421", "31f246aa-6b36-4d79-90bc-a2ec63eba0b8", "47c527b8-43af-451e-b533-6025a5a94ee9", "096e3de6-231e-44ff-aa56-12e0d56fb2be", "1c2464b8-5f35-4ecc-9a32-26023c21c13b", "7ba09eb8-f910-43c1-8b8a-d5d1a0d1cf3b", "aa33bccb-7133-4233-8e9a-ec32d6a92ece", "a2725962-e0a5-4d0b-a448-22e8dbd8c38e", "d1f418b5-3ddb-43ca-a856-50c12484f786", "e7a211ee-fe01-48c4-8e4b-36c43305c716", "51a72376-24a5-44f9-9cad-d2b5fbf2d6b8", "b69a61cf-d15a-4303-b547-4285c7ce4d92", "217089ee-4d2f-4aaa-869b-903f9e838382", "9f67c113-ecf0-4fbf-ab7e-d4c1f25c9b03", "a79b6b4a-b8e1-4c10-b652-77d434623ffb", "a3e2ae5f-196a-4e8f-aba6-2b34d2513625", "6d2d4c3c-656f-469d-9e75-1ec57c91e5b0", "5c87766f-ea6c-4f26-a84c-c6c825e1be3f", "82ea3fcb-a1d5-41ef-a7d6-83706a1df2d8", "5c701598-9bfa-4477-a0e8-c5fd4312b091"], "metadata": {"window": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, Turkey highly inflationary impact and LIFO expense (credit).  Adjusted gross profit\nmargin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP financial measures\nare useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "inherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "18", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f19bb5f4-e297-47b6-a6c3-62949b53b115": {"node_ids": ["d983686f-ceac-4f73-b65f-967f45efa739", "0ca314c1-5b19-41c7-9d7b-ea7cdcd38801", "5dad915d-60e4-40f6-bd62-46be6b5bbbc2", "0c591a12-3228-46d0-a3df-deebf0ca250c", "a2b870f8-2e84-4dc6-bc88-60fba1cdab90", "bfe6e382-b2de-4e8f-bf7d-26c19e92bdef", "f2a7c98e-ea5a-43f6-8c8e-70f93b13faf2", "f1e1e6c7-caca-4a49-8e71-ba108a0a4666", "eb273229-51cd-4ed0-8402-e4ca99af5659", "67ffbe03-8c49-4c3b-a433-47dd989d9f97", "43d09fe2-749c-4118-afb9-5a6ec11afc5a", "a6e64b94-7721-4ae6-af8b-22a7ff30243a", "efe8ceae-8693-4c3a-adc3-1bc2bf417d78", "c7891970-599d-40a6-bfd5-1006ce03b4a8", "b39c5648-72bf-401f-9f88-c421860a6ebe", "ffba1e90-2d40-4dbb-9810-a5a52c599848", "bb468a74-a11a-4bc1-acac-7c16a44523c1"], "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; Turkey highly inflationary impact; LIFO expense (credit); acquisition-\nrelated intangibles amortization; litigation and opioid-related expenses; acquisition, integration, and restructuring expenses;\nrecovery of a non-customer note receivable; impairment of assets; and the gain (loss) on the currency remeasurement related\nto Swiss tax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In\naddition, the per share impact of certain discrete tax expense primarily attributable to foreign valuation allowance\nadjustments for the three months ended December 31, 2021, and the per share impact of certain expenses relating to tax\nreform in Switzerland for the three months ended December 31, 2022 and 2021 are also excluded from adjusted diluted\nearnings per share. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "19", "file_name": "CEN-Q1-FY23-ECT.pdf", "file_path": "pdfs\\CEN-Q1-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 957076, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}